WO2002085384A2 - Lubricious coatings for substrates - Google Patents
Lubricious coatings for substrates Download PDFInfo
- Publication number
- WO2002085384A2 WO2002085384A2 PCT/CA2002/000546 CA0200546W WO02085384A2 WO 2002085384 A2 WO2002085384 A2 WO 2002085384A2 CA 0200546 W CA0200546 W CA 0200546W WO 02085384 A2 WO02085384 A2 WO 02085384A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antimicrobial
- coating
- substrate
- catheters
- antimicrobial metal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/16—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/14—Post-treatment to improve physical properties
- A61L17/145—Coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/30—Inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/10—Inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/082—Inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/452—Lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/624—Nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/63—Crystals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/15—Suppositories
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/31504—Composite [nonstructural laminate]
- Y10T428/31855—Of addition polymer from unsaturated monomers
Definitions
- the invention relates to water swellable or lubricious, antimicrobial and anti- inflammatory coatings for substrates such as medical devices, and methods of preparing same.
- Typical microorganisms involved in infection arising from the use of medical devices include Staphylococcus epidermidis, Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli and Proteus mirabilis, fungi and yeast such as Aspergillus fumigatus and Candida albicans.
- lubricious polymeric coatings are known for use on medical devices and other substrates. These coatings typically use a hydrophilic polymers which bind to the surface of the substrate and exhibit slipperiness (lubricity) on wetting. However, as a source for infection, these coatings can still be problematic.
- the present invention provides water swellable, and most preferably lubricious, coatings useful for a wide variety of substrates.
- the coatings contain a water swellable, preferably lubricious, polymer, which provides lubricity on wetting, and a nanocrystalline antimicrobial powder formed with atomic disorder, which acts as both an antimicrobial agent and an anti-inflammatory agent, without interfering with the enhanced lubricity. It is particularly surprising and advantageous to discover that the inclusion of the atomically disordered antimicrobial metal component of the coatings of the present invention adheres well to the substrates and does not interfere with the lubricity properties of the final, dried coating.
- the antimicrobial metal component provides not only antimicrobial activity, but also anti-inflammatory activity, when wetted.
- the coatings of the invention which are formed from solutions of the polymer and the metal powder and then dried, continue to provide both antimicrobial and anti-inflammatory activity when rehydrated for actual use.
- the initial hydration of the polymer and metal powder to form the coating does not deactivate the metal powder.
- the antimicrobial and anti-inflammatory activities are also found to be sustainable, that is not merely instantaneous, but continuing over an extended time period such as hours, days or weeks. Also important is the discovery that the coatings of the present invention provide a significant reduction to biofilm formation on the coated substrates.
- Nanocrystalline powders of the antimicrobial metal, most preferably a noble metal, formed with atomic disorder can be prepared either as nanocrystalline coatings on powdered substrates such as chitin, or may be prepared as nanocrystalline coatings on a substrate such as a silicon wafer, and then scraped off as a nanocrystalline powder.
- the coatings are formed with atomic disorder using such techniques as physical vapour deposition or modified inert gas condensation as taught in prior patent applications WO 93/23092, published November 25, 1993, and WO 95/13704, published May 26, 1995, both of which name Burrell et al., as inventors.
- a fine grained or nanocrystalline powder of the antimicrobial or noble metal may be cold worked to impart atomic disorder, as disclosed in prior patent application WO 93/23092.
- the metal powders may be formed in accordance with the novel powder manufacturing process disclosed herein.
- the invention provides a method of coating a substrate comprising forming a liquid medium containing a water swellable polymer (preferably a lubricious polymer), a solvent and a powder of one or more antimicrobial metals formed with atomic disorder; and coating the substrate from the liquid medium to provide a gel coating that adheres to the substrate, and becomes antimicrobial and anti-inflammatory when wet.
- a water swellable polymer preferably a lubricious polymer
- the invention provides a substrate coated with a water swellable gel coating, comprising a substrate, and a water swellable gel coating adhering to the substrate, wherein the coating includes a water swellable polymer and one or more antimicrobial metals formed with atomic disorder, and wherein the gel coating becomes antimicrobial and anti-inflammatory when wet.
- the invention provides a kit for coating a substrate comprising a water swellable polymer; a powder of one or more antimicrobial metals formed with atomic disorder; and optionally a solvent for the water swellable polymer.
- the lubricious polymer is preferably a hydrophilic polymer in powder form, most preferably one or more of carboxymethyl cellulose, polyvinyl alcohol and alginate.
- the antimicrobial metal is preferably one or more of Ag, Au, Pd or Pt (most preferably Ag), in a nanocrystalline powder form (grain size less than 100 nm, more preferably less than 50 nm, more preferably less than 40 nm, and most preferably less than 25 nm), and with particulate size preferably less than 100 ⁇ m, more preferably less than 40 ⁇ , and most preferably less than 10 ⁇ m).
- the invention also broadly provides a method of forming a metal powder comprising sputtering a metal coating in a sputtering apparatus equipped to sputter onto a moving or rotating surface, and then scraping the coating off the moving or rotating surface with one or more scrapers to form a metal powder.
- Metal or “metals” includes one or more metals whether in the form of substantially pure metals, alloys or compounds such as oxides, nitrides, borides, sulphides, halides or hydrides.
- Antimicrobial metals are silver, gold, platinum, palladium, iridium, zinc, copper, tin, antimony, bismuth, or mixtures of these metals with same or other metals, silver, gold, platinum and palladium being preferred, and silver being most preferred.
- Noble metals are silver, gold, platinum and palladium, or mixtures of such metals with same or other metals, with silver metal being the most preferred.
- Antimicrobial effect means that atoms, ions, molecules or clusters of the antimicrobial or noble metal are released into the electrolyte which the coating contacts in concentration sufficient to inhibit microbial growth on and in the vicinity of the coating.
- the most common methods of measuring an antimicrobial effect are a zone of inhibition test (which indicates an inhibitory effect, whether microbiostatic or microbiocidal) or a logarithmic reduction test (which indicates a microbiocidal effect).
- ZOI zone of inhibition test
- the material to be tested is placed on a bacterial lawn (or a lawn of other microbial species) and incubated. A relatively small or no ZOI (ex.
- a logarithmic reduction test in viable bacteria is a quantitative measure of the efficacy of an antibacterial treatment; for example, a 5 log reduction means a reduction in the number of microorganisms by 100,000-fold (e.g., if a product contained 100,000 pertinent microorganisms, a 5 log reduction would reduce the number of pertinent microorganisms to 1). Generally, a 3 log reduction represents a bactericidal effect.
- the logarithmic reduction test involves combining an inoculum of bacteria or other microbial species with the test treatment, incubating the inoculum with the test treatment, recovering the bacteria or other microbial species, and enumerating the bacteria or other microbial species using serial dilutions. Examples of these tests are set out in the examples which follow.
- Anti-inflammatory effect means a reduction in one ore more of the symptoms of erythema (redness), edema (swelling), pain and pruritus which are characteristic of inflammatory conditions.
- Biocompatible means generating no significant undesirable host response for the intended utility. Most preferably, biocompatible materials are non-toxic for the intended utility. Thus, for human utility, biocompatible is most preferably non-toxic to humans or human tissues.
- sustained release or “sustainable basis” are used to define release of atoms, molecules, ions or clusters of an antimicrobial or noble metal that continues over time measured in hours or days, and thus distinguishes release of such metal species from the bulk metal, which release such species at a rate and concentration which is too low to be therapeutically effective, and from highly soluble salts of antimicrobial or noble metals such as silver nitrate, which releases silver ions virtually instantly, but not continuously, in contact with an alcohol or electrolyte.
- Atomic disorder includes high concentrations of one or more of: point defects in a crystal lattice, vacancies, line defects such as dislocations, interstitial atoms, amorphous regions, grain and sub grain boundaries and the like relative to its normal ordered crystalline state. Atomic disorder leads to irregularities in surface topography and inhomogeneities in the structure on a nanometer scale.
- Normal ordered crystalline state means the crystallinity normally found in bulk metal materials, alloys or compounds formed as cast, wrought or plated metal products. Such materials contain only low concentrations of such atomic defects as vacancies, grain boundaries and dislocations.
- “Diffusion”, when used to describe conditions which limit diffusion in processes to create and retain atomic disorder, i.e., which freeze-in atomic disorder, means diffusion of atoms (adatom diffusion) and/or molecules on the surface or in the matrix of the material being formed.
- Alcohol or water-based electrolyte is meant to include any alcohol or water-based electrolyte that the antimicrobial materials of the present invention might contact in order to activate (i.e., cause the release of species of the anti-microbial metal) into same.
- the term is meant to include alcohols (generally short chain C 6 or less), water, gels, fluids, solvents, and tissues containing, secreting or exuding water, or water-based electrolytes, including body fluids (for example blood, urine or saliva), and body tissue (for example skin, muscle or bone).
- Bioabsorbable as used herein in association includes substrates which are useful in medical devices, that is which are biocompatible, and which are capable of bioabsorption in period of time ranging from hours to years, depending on the particular application.
- Bioabsorption means the disappearance of materials from their initial application site in the body (human or mammalian) with or without degradation of the dispersed polymer molecules.
- Cold working indicates that the material has been mechanically worked such as by milling, grinding, hammering, mortar and pestle or compressing, at temperatures lower than the recrystallization temperature of the material. This ensures that atomic disorder imparted through working is retained in the material.
- “Pharmaceutically- or therapeutically-acceptable” is used herein to denote a substance which does not significantly interfere with the effectiveness or the biological activity of the active ingredients (antimicrobial and anti-inflammatory activities) and which is not toxic or has an acceptable toxic profile to the host to which it is administered or contacted.
- “Therapeutically effective amount” is used herein to denote any amount of the nanocrystalline antimicrobial or noble metals which will exhibit an anti-microbial and an anti-inflammatory effect in use.
- the amount of the active ingredient, that is the antimicrobial or noble metal in the form of a coating, powder or dissolved in liquid solution, will vary with the substrate being coated, and the time which the substrate is to remain in contact with biological fluids and the like. Appropriate amounts in any given instance will be readily apparent to those skilled in the art or capable of determination by routine experimentation.
- Nanocrystalline is used herein to denote single-phase or multi-phase polycrystals, the grain size of which is less than about 100, more preferably ⁇ 50, even more preferably ⁇ 40, even more preferably ⁇ 30, and most preferably ⁇ 25 nanometers in at least one dimension.
- the term, as applied to the crystallite or grain size in the crystal lattice of coatings, powders or flakes of the antimicrobial or noble metals, is not meant to restrict the particle size of the materials when used in a powder form.
- Powder is used herein to include particulates of the nanocrystalline antimicrobial or noble metals ranging from nanocrystalline sized powders to flakes.
- powders of the antimicrobial or noble metals used in the present invention are sized at less than 100 ⁇ m, and more preferably less than 40 ⁇ m, and most preferably less than 10 ⁇ m.
- Gram size or “crystallite size” means the size of the largest dimension of the crystals in the antimicrobial or noble metal coating or powder.
- “Lubricous polymers” are polymers which become lubricious on wetting with water or a water or alcohol-based electrolyte. Most lubricious polymers are hydrophilic, by some hydrophobic polymers may also function as lubricious polymers if they have a sufficient degree of lubricity on wetting. "Hydrophilic” means that water droplets do not readily form beads on the surface of such hydrophilic material, but instead, the water droplets tend to assume a contact angle of less than 45 degrees and readily spread on its surface. The term “hydrophilic polymer” is meant to include polymers which are hydrophilic on wetting, and which also produce a lubricity in that wetted state.
- Hydrophilic polymer is also meant to include “water swellable” polymers, wherein “water swellable” means a substantially hydrophilic polymer which, even though not soluble in water, absorbs sufficient water to render it lubricious in the hydrated state. While these definitions all refer to water as an agent for hydration, it should be understood to include other water or alcohol-based electrolytes including bodily fluids which are capable of hydrating or swelling the polymer.
- solvent is the term used herein to describe the liquid medium used to solubilize, disperse or suspend the components of the coatings of the present invention prior to applying the coating to the substrate.
- the term does not imply that the components of the coatings are completely dissolved in the solvent, it is sufficient that the polymer is approximately 1 wt % soluble in the solvent, more preferably at least 2 wt % soluble in the solvent, or is otherwise effective in promoting some swelling of the polymer.
- nanocrystalline antimicrobial metal and similar terminology such as “nanocrystalline coatings or powders” is meant to refer to antimicrobial metals formed with atomic disorder and having nanocrystalline grain size.
- kit is meant to refer to a package or container with ingredients for a coating of the present invention or containing a coated substrate, whether the ingredients are in separate phases or containers, or mixed together.
- the lubricious gel coatings of the present invention are prepared by mixing one or more suitable lubricious polymers with the atomically disordered antimicrobial or noble metals in a suitable solvent, and then using this mixture to coat the substrate.
- the solvent does not need to dissolve the individual components, but rather is suitable provided it can provide the two components in a suspension which at least partially hydrates the polymer, and does not interfere with the end activity of any of the components.
- the individual components of the lubricous coating may be provided in kit form such that the mixture and coating are prepared by the end user close to the time of use, or the kit may include the coating components in a pre-mixed form.
- the solvent is one suitable for suspending the components of the coatings without interfering with the antimicrobial, anti-inflammatory activities or the desired biocompatible and lubricious properties of the final coating.
- exemplary solvents include esters, toluene, lactones, dimethylformamide, halogenated solvents, tetrahydrofuran, dioxane, alkyl acetates, acetonitrile, butyrolactone, ethyl acetate, chloroform, methanol, ethanol, propanol, DMSO (dimethyl sulfoxide) and mixtures thereof.
- Preferred solvents are water (preferably nanopure), and alcohols such as methanol, ethanol and propanol, and DMSO, with water being most preferred.
- the substrate may be formed of virtually any material, including polyurethane, polyvinylchloride, other vinyl polymers, polycarbonate, polystyrene, nylon, polyesters and polyacrylates, polypropylene, polybutylene, tetrafluoroethylene, polyvinylacetal, elastomers, latex rubber, rubber, silicone, other plastic, metal, glass, and composites.
- the substrate to be coated is any medical device or other substrate which will benefit from the provision of a lubricious coating, whether implantable, percutaneous, transcutaneous or surface applied.
- Particular substrates which may be coated include catheters (including urinary, in-dwelling, drainage catheters, etc.), bone screws, total joints, vascular grafts, soft tissue repair implants such as hernia meshes, guide wires, needles, wound drains, pacemaker leads, condoms, contact lenses, peristaltic pump chambers, arteriovenous shunts, gastroenteric feed tubes, endotracheal tubes, gloves and implants.
- Additional substrates which can be coated include venous catheters, arterial catheters, central line and peripheral line catheters, halo screws, cannulas, endoscopes, laparoscopes, sutures, staples, myringotomy tubes, nasal packings, dressings and gauze.
- the lubricious polymers suitable for use in accordance with the present invention are water-soluble or water-swellable polymers which are substantially more lubricious when wetted with water, or with a water or alcohol-based electrolyte, than when dry. Such polymers are well known in the art.
- hydrophilic polymers including sodium, potassium and calcium alginates, carboxymethylcellulose, agar, gelatin, polyvinyl alcohol, collagen, pectin, chitin, chitosan, poly ( ⁇ -amino acids), polyester, poly-1-caprolactone, polyvinylpyrrolidone, polyethylene oxide, polyvinyl alcohol, polyether, polysaccharide, hydrophilic polyurethane, polyhydroxyacrylate, polymethacrylate, dextran, xanthan, hydroxypropyl cellulose, methyl cellulose, and homopolymers and copolymers of N-vinylpyrrolidone, N-vinyllactam, N-vinyl butyrolactam, N-vinyl caprolactam, other vinyl compounds having polar pendant groups, acrylate and methacrylate having hydrophilic esterifying groups, hydroxyacrylate, and acrylic acid, and combinations thereof.
- Most preferred lubricious polymers include hydrocolloid powders such as sodium, potassium and calcium alginates, polyvinyl alcohol, and carboxymethylcellulose.
- Other preferred lubricious polymers are cellulose and derivatives thereof, starch, glycogen, gelatin, pectin, chitosan, chitin, collagen, gum arabic, locust bean gum, karaya gum, gum tragacanth, ghatti gum, agar-agar, carrageenans, alginates, carob gum, guar gum, xanthan gum, poly ( ⁇ - amino acids), polyester and poly-1-caprolactone.
- the lubricious polymers may be physically stabilized by cross-linking, as is known in the art.
- the lubricious coatings of the present invention are prepared from a liquid medium which contains a solvent capable of forming a solution, dispersion, suspension or emulsion of the polymer and metal components of the coating.
- the liquid medium has a gellike consistency, and can be used in this form in some applications, such as gloves.
- the coatings can then be readily applied to a substrate by dipping, spraying, knife coating, roller coating, smearing or the like. Dipping is particularly preferred.
- the substrate should be thoroughly cleaned to remove surface impurities which could interfere with adhesion. It is recommended that various plastic or polymeric substrates be treated with oxidizing solutions prior to the coating application. For instance, natural rubber can be treated with a sodium chlorate solution.
- the process of applying the coating to the substrate is preferably conducted at atmospheric pressure and at temperatures between about 0 and 50° C, more preferably between about 10 and 40°C.
- the wet coated substrate can be used in that state, while in other applications, the coating is preferably dried at a temperature below the recrystallization temperature of the antimicrobial or noble metal (i.e., at a temperature below that which would anneal out the atomic disorder).
- the coating is dried at -80 to 50°C, more preferably between 10 and 40° C. Most preferably, the coating is air dried at room temperature.
- the concentration of the polymers in the liquid medium is sufficient to provide the desired amount of lubricity in the final coating.
- the concentration of the polymers will range from about 0.1 to 10 wt %, more preferably 0.5 to 5 wt%.
- the concentration of the antimicrobial or noble metal is sufficient to provide the desired antimicrobial and anti- inflammatory activities in the final coating.
- the concentration will range from about 0.001 to 30 wt %, more preferably 0.1 to 5 wt %.
- Binders for improved adhesion to the substrate may be included.
- the binder may be applied to the substrate simultaneously or prior to the coating.
- preservatives such as methyl paraben and propyl paraben, texturizing agents, thickeners, anticoagulants such as heparin, ⁇ -glucan, hormones, hyaluronic acid, cytokines such as epidermal growth factor, platelet derived growth factor, transforming growth factor and interleukins, and bone morphogenetic proteins, and the like.
- Polyvinyl alcohol is a particularly preferred polymer and also acts as a texturizing agent
- methyl or propyl parabens are particularly preferred preservatives.
- These other agents may be included in amounts in the range of 0.1 to 5 wt %, or any therapeutically acceptable amount.
- All agents, solvents and components used in the coatings of the present invention must be non-toxic and physiologically acceptable for the intended purpose, and must not substantially interfere with the activity of the coating so as to deleteriously affect the lubricity, the antimicrobial effect or the anti-inflammatory activity. Ingredients are thus only included in therapeutically or pharmaceutically acceptable amounts. Ingredients to be avoided or limited in the coatings of the present invention, preferably to less than 0.01 wt %, are glycerin, glycerols, chloride salts, aldehydes, ketones, long chain alcohols, and triethanolamine.
- the substrate coated with the lubricious gel coatings of the present invention may be used in their initial wetted state, but are more preferably dried and then rehydrated in use. Powders of Atomically Disordered Antimicrobial or Noble Metals
- Crystalline powder forms of the antimicrobial or noble metals can be prepared as free standing powders, by coating powdered substrates, or from coatings on substrates which are then collected, for example by scraping, and then sized.
- the powders may be prepared as pure metals, metal alloys or compounds such as metal oxides or metal salts, by vapour deposition, mechanical working, or compressing to impart the atomic disorder.
- the crystalline powders are formed with atomic disorder in accordance with the techniques published in the prior patent applications of Burrell et al, see for example WO 93/23092, published November 25, 1993, and WO 95/13704, published May 26, 1995.
- the atomic disorder will most typically be formed in the metal powders during physical vapour deposition as set out below or by mechanically imparting the disorder, such as by milling, grinding, hammering, mortar and pestle or compressing, under conditions of low temperature (i.e., temperatures less than the temperature of recrystallization of the material) to ensure that annealing or recyrstallization does not take place.
- the powders may be formed by inert-gas condensation techniques, which are modified to provide atomic disorder in the powder produced, as taught in WO 95/13704 to Burrell et al.
- Powders of the antimicrobial or noble metals are preferably formed by physical vapour deposition (PND) onto a substrate such as a cold finger, a silicon wafer, solid plates, a rotating cylinder, a continuous belt in a roll coater, or on steel collectors in known PND coaters.
- PND physical vapour deposition
- Preparation of powders of the present invention by sputtering onto a continuous belt in a roll coater, or other some other moving or rotating substrate surface is particularly advantageous, inasmuch as it can quickly and easily yield a relatively large supply of freestanding powder at a relatively low cost.
- a stainless steel belt can be used in the roll coating process without the need to provide additional cooling of the substrate.
- the powders or coatings and then are then scraped off to form a powder, and may be sized to avoid overly large particulates.
- the powders are scraped off the moving surface with scrapers which contact the moving surface at an angle sufficient to remove the coating in flake or powder form.
- the coating may be scraped off with scrapers angled for forward cutting of the coating from the moving surface, or with scrapers which remove the coating from the moving surface by reverse dragging action on the surface.
- the scrapers may be suspended above the belt, and either weighted or spring loaded to apply pressure sufficient to remove the coating from the moving surface. With a continuous belt, the scrapers can conveniently be located above the end rollers to remove the coating with a reverse dragging action as the belt rounds the end roller.
- the powders of the antimicrobial or noble metals may be formed on powdered substrates which are biocompatible, or otherwise compatible for the end use of the lubricious coating.
- powdered substrates are hydrocolloids, particularly those which are bioabsorbable and/or hygroscopic powders such as chitin.
- Exemplary bioabsorbable and/or hygroscopic powders are composed of :
- Synthetic Bioabsorbable Polymers for example polyesters/polyactones such as polymers of polyglycolic acid, glycolide, lactic acid, lactide, dioxanone, trimethylene carbonate etc., poly anhydrides, polyesteramides, polyortheoesters, polyphosphazenes, and copolymers of these and related polymers or monomers.
- Proteins albumin, fibrin, collagen, elastin;
- Polysaccharides chitosan, alginates, hyaluronic acid;
- Biosynthetic Polyesters 3-hydroxybutyrate polymers.
- the preferred conditions which are used to create atomic disorder during a physical vapour deposition process include:
- a low substrate temperature that is maintaining the surface to be coated at a temperature such that the ratio of the substrate temperature to the melting point of the metal (in degrees Kelvin) is less than about 0.5, more preferably less than about 0.35 and most preferably less than about 0.3; and optionally one or both of:
- a higher than normal working gas pressure i.e., for vacuum evaporation: e-beam or arc evaporation, greater than 0.001 Pa (0.01 mT), gas scattering evaporation (pressure plating) or reactive arc evaporation, greater than 2.67 Pa (20 mT); for sputtering: greater than 10 Pa (75 mT); for magnetron sputtering: greater than about 1.33 Pa (10 mT); and for ion plating: greater than about 26.67 Pa (200 mT); and
- the therapeutic effects of the material so produced is achieved when the lubricous coating is brought into contact with an alcohol or a water-based electrolyte, thus releasing metal ions, atoms, molecules or clusters.
- concentration of the metal species which is needed to produce a therapeutic effect will vary from metal to metal.
- the ability to achieve release of metal atoms, ions, molecules or clusters on a sustainable basis from a metal powder component is dictated by a number of factors, including PND coating characteristics such as composition, structure, solubility and thickness, and the nature of the environment in which the device is used.
- PND coating characteristics such as composition, structure, solubility and thickness, and the nature of the environment in which the device is used.
- the level of atomic disorder is increased, the amount of metal species released per unit time increases. For instance, a silver metal film deposited by magnetron sputtering at T/Tm ⁇ 0.5 and a working gas pressure of about 0.93 Pa (7 mT) releases approximately 1/3 of the silver ions that a film deposited under similar conditions, but at 4 Pa (30 mT), will release over 10 days. Films that are created with an intermediate structure (ex.
- the time required for total dissolution will be a function of film thickness and the nature of the environment to which they are exposed.
- the relationship in respect of thickness is approximately linear, i.e. a two fold increase in film thickness will result in about a two-fold increase in longevity.
- a coating deposited by magnetron sputtering such that the working gas pressure was low (ex. 2 Pa or 15 mT) for 50% of the deposition time and high (ex. 4 Pa or 30 mTorr) for the remaining time, has a rapid initial release of metal ions, followed by a longer period of slow release.
- This type of PND coating is extremely effective for devices such as urinary catheters for which an initial rapid release is required to achieve immediate anti-microbial concentrations followed by a lower release rate to sustain the concentration of metal ions over a period of weeks.
- the substrate temperature used during vapour deposition should not be so low that annealing or recrystallization of the PVD coating takes place as the coating warms to ambient temperatures or the temperatures at which it is to be used (ex. body temperature).
- This allowable ⁇ T that the temperature differential between the substrate temperature during deposition and the ultimate temperature of use, will vary from metal to metal.
- metal For the most preferred metal, Ag, preferred substrate temperatures of -20 to 200°C , more preferably -10°C to 100°C are used.
- Atomic order may also be achieved by preparing composite metal materials, that is materials which contain one or more antimicrobial or noble metals in a metal matrix which includes atoms or molecules different from the antimicrobial or noble metals.
- the preferred technique for preparing a composite material is to co- or sequentially deposit the antimicrobial or noble metal(s) with one or more other inert, biocompatible metals selected from Ta, Ti, Nb, Zn, V, Hf, Mo, Si, Al and alloys of these metals or other metal elements, typically other transition metals.
- inert metals have a different atomic radii from that of the antimicrobial or noble metals, which results in atomic disorder during deposition. Alloys of this kind can also serve to reduce atomic diffusion and thus stabilize the disordered structure.
- Thin film deposition equipment with multiple targets for the placement of each of the antimicrobial or noble and biocompatible metals is preferably utilized.
- the layer(s) of the biocompatible metal(s) should be discontinuous, for example as islands within the antimicrobial or noble metal matrix.
- the final weight ratio of the antimicrobial or noble metal(s) to biocompatible metal(s) should be greater than about 0.2.
- the most preferable biocompatible metals are Ti, Ta, Zn and Nb. It is also possible to form the anti-microbial coating from oxides, carbides, nitrides, sulphides, borides, halides or hydrides of one or more of the antimicrobial or noble metals and/or one or more of the biocompatible metals to achieve the desired atomic disorder.
- Another composite material may be formed by reactively co- or sequentially depositing, by physical vapour techniques, a reacted material into the thin film of the antimicrobial or noble metal (s).
- the reacted material is an oxide, nitride, carbide, boride, sulphide, hydride or halide of the antimicrobial or noble and/or biocompatible metal, formed in situ by injecting the appropriate reactants, or gases containing same, (ex. air, oxygen, water, nitrogen, hydrogen, boron, sulphur, halogens) into the deposition chamber. Atoms or molecules of these gases may also become absorbed or trapped in the metal film to create atomic disorder.
- the reactant may be continuously supplied during deposition for codeposition or it may be pulsed to provide for sequential deposition.
- the final weight ratio of reaction product to antimicrobial or noble metal(s) should be greater than about 0.05. Air, oxygen, nitrogen and hydrogen are particularly preferred reactants, with oxygen being most preferred.
- the above deposition techniques to prepare composite PND coatings may be used with or without the conditions of lower substrate temperatures, high working gas pressures and low angles of incidence previously discussed. One or more of these conditions are preferred to retain and enhance the amount of atomic disorder created in the coating.
- powders of the present invention are sized at less than 100 ⁇ m, and more preferably less than 40 ⁇ m, and most preferably about 3 - 5 ⁇ m in size to avoid being abrasive in the coating.
- the antimicrobial and anti-inflammatory effects of the nanocrystalline powder is achieved when the lubricous coating, and thus the powder, is brought into contact with an alcohol or a water-based electrolyte, thus releasing the antimicrobial or noble metal ions, atoms, molecules or clusters. Sterilization and Packaging
- Powders of the antimicrobial or noble metal formed with atomic disorder or the substrates formed with the lubricious coatings of this invention are preferably sterilized without applying excessive thermal energy, which can anneal out the atomic disorder, thereby reducing or eliminating a useful release of antimicrobial or noble metal species.
- Gamma radiation is preferred for sterilizing such dressings, as discussed in WO 95/13704. Electron beam and ethylene oxide sterilization techniques can also be used.
- the sterilized coating materials, or the coated substrates should be sealed in packaging, containers or kits which limit moisture and light penetration to avoid additional oxidation or reduction of the antimicrobial metal.
- Polyester peelable pouches are exemplary.
- Nanocrystalline silver coatings were prepared by sputtering silver in an oxygen- containing atmosphere directly onto an endless stainless steel belt of a magnetron sputtering roll coater, or onto silicon wafers on the belt.
- the belt did not need to be cooled.
- the coatings were scraped off with the belt with suspended and weighted metal scrapers which dragged along the coating in a reverse direction as the belt rounded the end rollers.
- the coatings were scraped off with a knife edge.
- the sputtering conditions were as follows:
- Target Size (individual, 23 targets): 15.24 cm X 1216.125 cm
- the powder had a particle size ranging from 2 ⁇ m to 100 ⁇ m, with grain or crystallite size of 8 to 10 nm (i.e., nanocrystalline), and demonstrated a positive rest potential.
- a gel was made using carboxymethyl cellulose (2%), polyvinyl alcohol (0.5%), methyl paraben (0.1%), propyl paraben (0.02%), nanocrystalline silver powder of Example 1 (0.1%) and water (all amounts in weight percentages).
- segments (2cm) of latex foley catheters 14 French were dipped coated and allowed to dry at room temperature for 24h.
- the segments were then tested for antimicrobial effect, using a corrected zone of inhibition technique, against Pseudomonas aeruginosa and Staphylococcus aureus.
- the corrected zone of inhibition method involved growing a culture of the bacterium of interest in Tryptic Soy Broth for 16 hours at 37 °C.
- a gel was made using carboxymethyl cellulose (2%), nanocrystalline silver powder of Example 1 (0.1 %) and water. After mixing the gel well, to distribute the nanocrystalline silver powder, segments (2cm) of latex foley catheters (14 French) were dipped coated and allowed to dry at room temperature for 24h. The segments were then tested for antimicrobial efficacy, using a corrected zone of inhibition technique, against Pseudomonas aeruginosa and Staphylococcus aureus. The corrected zone of inhibition method involved growing a culture of the bacterium of interest in Tryptic Soy Broth for 16 hours at 37 °C.
- a gel was made using sodium alginate (2%), nanocrystalline silver powder of Example 1 (0.1%) and water. After mixing the gel well, to distribute the nanocrystalline silver powder, segments (2cm) of latex foley catheters (14 French) were dipped coated and allowed to dry at room temperature for 24h. The segments were then tested for antimicrobial efficacy, using a corrected zone of inhibition technique, against Pseudomonas aeruginosa and Staphylococcus aureus. The corrected zone of inhibition method involved growing a culture of the bacterium of interest in Tryptic Soy Broth for 16 hours at 37 °C.
- Example 3 Five Bard latex urinary catheters were coated with a CMC-Ag gel using a method as described in Example 3 and another five catheters were coated an alginate -Ag gel using a method as described in Example 4. The coated catheters were tested for lubricity with five uncoated latex catheters as controls.
- No. 1 - A commercial carboxymethyl cellulose/pectin gel (Duoderm®, Convatec) was combined with nanocrystalline silver powder prepared as set forth in Example 1 to produce a gel with 0.1% silver.
- a logarithmic reduction test was performed as follows in the gel using Pseudomonas aeruginosa.
- the inoculum was prepared by placing 1 bacteriologic loopful of the organism in 5 ml of trypticase soy broth and incubating it for 3-4 h. The inoculum (0.1 ml) was then added to 0.1 ml of gel and vortexed (triplicate samples). The mixture was incubated for one-half hour.
- No. 3 An alginate fibrous substrate was directly coated with an atomic disordered nanocrystalline silver coating using magnetron sputtering conditions similar to those set forth in Example 1.
- the alginate (5.7 g) was added to 100 mL volume of water to create a gel.
- This material was tested using the method of No. 1.
- the material generated a 5.2 logarithmic reduction of Pseudomonas aeruginosa, demonstrating that the gel had a significant bactericidal effect.
- the well was filled with either 0.1 mL of the silver containing gel, a mupirocin containing cream or a mupirocin containing ointment.
- the Petri plates were then incubated for 24 h and the diameter of the zone of inhibition was measured and recorded.
- the silver containing gel produced 9 mm zone of inhibition against both Pseudomonas aeruginosa and Staphylococcus aureus, while the mupirocin cream and ointment produced 42 and 48 mm zones against Staphylococcus aureus and 0 mm zones against Pseudomonas aeruginosa.
- the silver containing gel reduced the Pseudomonas aeruginosa and Staphylococcus aureus properties by 4.4 and 0.6 log reductions, respectively, showing good bactericidal activity.
- the mupirocin cream and ointment generated 0.4 and 0.8, and 0.8 and 1.6, log reductions against Staphylococcus aureus and Pseudomonas aeruginosa, respectively.
- the silver gel had both a greater bactericidal effect and spectrum of activity than the mupirocin containing products.
- Nos. 5-10 The formula for Nos. 5-10 are summarized in Table 3. Zones of inhibitions were determined as in No. 4 and log reductions were determined as in No. 1.
- No. 11- A commercially available gel (glyceryl polymethacrylate) was blended with Silver powder to produce a gel with a silver content of 0.1%. This gel was tested as in Nos. 5-10 and was found to produce zones of 15 mm against both Staphylococcus aureus and Pseudomonas aeruginosa. Log reductions of 1.1 and >5 were produced against Staphylococcus aureus and Pseudomonas aeruginosa. This gel product had a greater spectrum of activity than did mupirocin cream or ointment.
- the silver gel solutions of No. 1 - 11 can be applied to substrates by hydrating and comminuting the coated substrate where needed and then drying the gel solution onto substrates to provide lubricious coatings of the present invention.
- the silver gels also have an anti-inflammatory effect, with reduction of edema and erythema symptoms.
- No. 12 - A gel coat for a urinary catheter was prepared using the formula in No. 6. The coating was applied to the catheter using a dipping method. The coating was air dried overnight. The dried gel coat was smooth and easy to handle. It was not tacky to touch and had excellent abrasion and adhesion properties. Upon re wetting, the surface became extremely slippery indicating excellent lubricious properties.
- a zone of inhibition test was performed against Pseudomonas aeruginosa using an inoculum as prepared in No. 1.
- the inoculum (0.1 mL) was spread over the surface of Mueller-Hinton agar in a Petri plate.
- the catheter was cut into 1" segments which were laid on their side into the middle of the Petri plate.
- Petri plates were incubated for 24 h and then the zone of inhibitions was measured. In all cases, zones of inhibition were generated that ranged from 7-10 mm. This indicates that wetting, drying and rehydrating had no negative effect on the antimicrobial activity of the gel coat.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002249046A AU2002249046A1 (en) | 2001-04-23 | 2002-04-23 | Lubricious coatings for substrates |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28588401P | 2001-04-23 | 2001-04-23 | |
US09/840,637 | 2001-04-23 | ||
US60/285,884 | 2001-04-23 | ||
US09/840,637 US7008647B2 (en) | 2001-04-23 | 2001-04-23 | Treatment of acne |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002085384A2 true WO2002085384A2 (en) | 2002-10-31 |
WO2002085384A3 WO2002085384A3 (en) | 2003-08-21 |
Family
ID=26963436
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/012690 WO2002085299A2 (en) | 2001-04-23 | 2002-04-23 | Therapeutic treatments using the direct application of antimicrobial metal compositions |
PCT/CA2002/000547 WO2002085385A2 (en) | 2001-04-23 | 2002-04-23 | Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa |
PCT/CA2002/000548 WO2002085386A2 (en) | 2001-04-23 | 2002-04-23 | Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue |
PCT/CA2002/000549 WO2002085387A2 (en) | 2001-04-23 | 2002-04-23 | A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent ans their use in the treatment of inflammatory skin conditions |
PCT/CA2002/000546 WO2002085384A2 (en) | 2001-04-23 | 2002-04-23 | Lubricious coatings for substrates |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/012690 WO2002085299A2 (en) | 2001-04-23 | 2002-04-23 | Therapeutic treatments using the direct application of antimicrobial metal compositions |
PCT/CA2002/000547 WO2002085385A2 (en) | 2001-04-23 | 2002-04-23 | Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa |
PCT/CA2002/000548 WO2002085386A2 (en) | 2001-04-23 | 2002-04-23 | Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue |
PCT/CA2002/000549 WO2002085387A2 (en) | 2001-04-23 | 2002-04-23 | A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent ans their use in the treatment of inflammatory skin conditions |
Country Status (9)
Country | Link |
---|---|
US (9) | US6723350B2 (en) |
EP (4) | EP1383522B1 (en) |
JP (4) | JP2004529929A (en) |
AT (1) | ATE322274T1 (en) |
AU (4) | AU2002252881B2 (en) |
CA (4) | CA2445729C (en) |
DE (1) | DE60210441T2 (en) |
ES (1) | ES2261659T3 (en) |
WO (5) | WO2002085299A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
US7763769B2 (en) | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
EP2575915A2 (en) * | 2010-06-04 | 2013-04-10 | Smiths Medical ASD, Inc. | Antimicrobial lubricant |
CN103501827A (en) * | 2011-03-30 | 2014-01-08 | 大和纺控股株式会社 | Wound-covering material |
US8865227B2 (en) | 2007-12-20 | 2014-10-21 | Smith & Nephew (Overseas) Limited | Metal carbonate particles and methods of making thereof |
RU2659580C1 (en) * | 2017-10-16 | 2018-07-05 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) | Method for obtaining agent for topical treatment of skin lesions based on nanoscale silver particles, ointment base and solid additives |
Families Citing this family (308)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9119705B2 (en) | 1998-06-08 | 2015-09-01 | Thermotek, Inc. | Method and system for thermal and compression therapy relative to the prevention of deep vein thrombosis |
US7135195B2 (en) * | 1999-06-01 | 2006-11-14 | American Silver, Llc | Treatment of humans with colloidal silver composition |
US7179849B2 (en) * | 1999-12-15 | 2007-02-20 | C. R. Bard, Inc. | Antimicrobial compositions containing colloids of oligodynamic metals |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US20030185901A1 (en) * | 2000-07-27 | 2003-10-02 | Burrell Robert E. | Methods of treating conditions with a metal-containing material |
US7008647B2 (en) * | 2001-04-23 | 2006-03-07 | Nucryst Pharmaceuticals Corp. | Treatment of acne |
US7427416B2 (en) * | 2000-07-27 | 2008-09-23 | Nucryst Pharmaceuticals Corp. | Methods of treating conditions using metal-containing materials |
US20060115541A1 (en) * | 2000-07-27 | 2006-06-01 | Gillis Scott H | Treatment of bladder conditions |
DE10043151A1 (en) * | 2000-08-31 | 2002-03-28 | Peter Steinruecke | Bone cement with antimicrobial effectiveness |
JP2004529929A (en) * | 2001-04-23 | 2004-09-30 | ニュクリスト ファーマシューティカルズ コーポレーション | Use of metals for induction of apoptosis and inhibition of matrix metalloproteinases |
US20040092890A1 (en) * | 2001-05-10 | 2004-05-13 | Ash Stephen R. | Catheter lock solution including a photo-oxidant |
AU2002345328A1 (en) | 2001-06-27 | 2003-03-03 | Remon Medical Technologies Ltd. | Method and device for electrochemical formation of therapeutic species in vivo |
US20030059375A1 (en) * | 2001-08-20 | 2003-03-27 | Transave, Inc. | Method for treating lung cancers |
DE10146050B4 (en) * | 2001-09-18 | 2007-11-29 | Bio-Gate Ag | Process for the preparation of an antimicrobial adhesive and coating material |
JP3795364B2 (en) * | 2001-09-27 | 2006-07-12 | シャープ株式会社 | Integrated circuit and receiver |
CN1612804A (en) | 2001-12-03 | 2005-05-04 | C·R·巴德公司 | Microbe-resistant medical device, microbe-resistant polymeric coating and methods for producing same |
TWI255224B (en) * | 2002-01-09 | 2006-05-21 | Novartis Ag | Polymeric articles having a lubricious coating and method for making the same |
US8118789B2 (en) * | 2002-02-20 | 2012-02-21 | Abbott Research Group, Inc. | Deodorizer devices and systems for controlling perspiration-related body odor |
US7270653B2 (en) * | 2002-02-20 | 2007-09-18 | Abbott Research Group | Methods of treating abnormal biological conditions using metal oxides |
US6589216B1 (en) | 2002-02-20 | 2003-07-08 | Abbott Research Group, Inc. | Vaginal douches, vaginal douche applicators and methods of vaginal douching |
US7201925B2 (en) * | 2002-04-23 | 2007-04-10 | Nueryst Pharmaceuticals Corp. | Treatment of ungual and subungual diseases |
US20060102385A1 (en) * | 2002-06-21 | 2006-05-18 | Andreas Heise | Printed board for electronic devices controlling a motor vehicle |
US6865810B2 (en) * | 2002-06-27 | 2005-03-15 | Scimed Life Systems, Inc. | Methods of making medical devices |
MXPA05001312A (en) * | 2002-08-02 | 2005-08-03 | Transave Inc | Platinum aggregates and process for producing the same. |
US9186322B2 (en) * | 2002-08-02 | 2015-11-17 | Insmed Incorporated | Platinum aggregates and process for producing the same |
US8404751B2 (en) * | 2002-09-27 | 2013-03-26 | Hallux, Inc. | Subunguicide, and method for treating onychomycosis |
US7485259B2 (en) * | 2002-10-08 | 2009-02-03 | Eldred Bradley J | Organic compound and metal ion synergistic disinfection and purification system and method of manufacture |
EP1576528A4 (en) * | 2002-10-09 | 2011-05-18 | California Inst Of Techn | Sensor web |
WO2004037187A2 (en) * | 2002-10-22 | 2004-05-06 | Nucryst Pharmaceuticals Corp. | Metal-containing materials, compositions and methods |
JP2006509738A (en) * | 2002-10-22 | 2006-03-23 | ニュクリスト ファーマシューティカルズ コーポレーション | Prophylactic treatment |
US8066854B2 (en) * | 2002-12-18 | 2011-11-29 | Metascape Llc | Antimicrobial coating methods |
US8309117B2 (en) | 2002-12-19 | 2012-11-13 | Novartis, Ag | Method for making medical devices having antimicrobial coatings thereon |
US7666410B2 (en) | 2002-12-20 | 2010-02-23 | Kimberly-Clark Worldwide, Inc. | Delivery system for functional compounds |
US8409618B2 (en) * | 2002-12-20 | 2013-04-02 | Kimberly-Clark Worldwide, Inc. | Odor-reducing quinone compounds |
US20040151716A1 (en) * | 2003-02-03 | 2004-08-05 | Hamer Richard A. | Material and method for treating microbial mediated dermatological conditions |
ATE354380T1 (en) * | 2003-02-03 | 2007-03-15 | Polaschegg Hans-Dietrich Dr Te | COMPOSITION FOR THE PREVENTION OF INFECTIONS THROUGH SUBCUTANEOUS PROSTHESIS |
US20040156874A1 (en) * | 2003-02-11 | 2004-08-12 | Bradley Pharmaceuticals, Inc. | Urea- a topical anti-inflammatory |
CN1744917B (en) * | 2003-02-26 | 2010-05-05 | 大塚制药株式会社 | Sustained-release pharmaceutical composition for lung administration |
US20040180093A1 (en) * | 2003-03-12 | 2004-09-16 | 3M Innovative Properties Company | Polymer compositions with bioactive agent, medical articles, and methods |
US7488757B2 (en) * | 2003-03-24 | 2009-02-10 | Becton, Dickinson And Company | Invisible antimicrobial glove and hand antiseptic |
US20040236290A1 (en) * | 2003-04-23 | 2004-11-25 | Zimmermann Stephan A. | Minimally invasive vascular apparatus modified to minimize scarring at introduction site |
US6874165B2 (en) * | 2003-05-19 | 2005-04-05 | Mao-Sheng Lee | Modified NBR gloves |
CA2526150C (en) | 2003-06-03 | 2014-05-06 | American Biotech Labs | Treatment of humans with colloidal silver composition |
PL1644024T3 (en) | 2003-06-06 | 2020-03-31 | Board Of Regents, The University Of Texas System | Antimicrobial flush solutions |
DE10328261B4 (en) * | 2003-06-23 | 2007-10-25 | Beiersdorf Ag | Disinfecting coating with silver coating and its use |
NZ543643A (en) * | 2003-06-23 | 2007-09-28 | Beiersdorf Ag | Antimicrobial wound dressing with two layers and antimicrobial metal between layers but not on exterior |
US7480530B2 (en) * | 2003-06-30 | 2009-01-20 | Johnson & Johnson Consumer Companies, Inc. | Device for treatment of barrier membranes |
US8734421B2 (en) * | 2003-06-30 | 2014-05-27 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating pores on the skin with electricity |
US20050025817A1 (en) * | 2003-07-03 | 2005-02-03 | Bhatia Kuljit S. | Delivery system for topical medications |
US8128672B2 (en) | 2006-05-09 | 2012-03-06 | Thermotek, Inc. | Wound care method and system with one or both of vacuum-light therapy and thermally augmented oxygenation |
US8574278B2 (en) * | 2006-05-09 | 2013-11-05 | Thermotek, Inc. | Wound care method and system with one or both of vacuum-light therapy and thermally augmented oxygenation |
DK200301128A (en) * | 2003-08-05 | 2005-02-06 | Thomsen Joern Oddershede | Grant Preparation |
US20050028563A1 (en) * | 2003-08-08 | 2005-02-10 | Milliken & Company | Garment for use with sensitive skin, and method and fabric for us in making same |
DE10340277B4 (en) * | 2003-08-29 | 2006-11-23 | Bio-Gate Bioinnovative Materials Gmbh | Personal care products containing silver agglomerates |
US8519146B2 (en) * | 2004-09-07 | 2013-08-27 | The University Of Akron | Metal complexes of N-heterocyclic carbenes as antibiotics |
US20050054774A1 (en) * | 2003-09-09 | 2005-03-10 | Scimed Life Systems, Inc. | Lubricious coating |
US7678367B2 (en) | 2003-10-16 | 2010-03-16 | Kimberly-Clark Worldwide, Inc. | Method for reducing odor using metal-modified particles |
US7794737B2 (en) | 2003-10-16 | 2010-09-14 | Kimberly-Clark Worldwide, Inc. | Odor absorbing extrudates |
US7879350B2 (en) | 2003-10-16 | 2011-02-01 | Kimberly-Clark Worldwide, Inc. | Method for reducing odor using colloidal nanoparticles |
US7745509B2 (en) * | 2003-12-05 | 2010-06-29 | 3M Innovative Properties Company | Polymer compositions with bioactive agent, medical articles, and methods |
US20050123590A1 (en) * | 2003-12-05 | 2005-06-09 | 3M Innovative Properties Company | Wound dressings and methods |
US20050123621A1 (en) * | 2003-12-05 | 2005-06-09 | 3M Innovative Properties Company | Silver coatings and methods of manufacture |
WO2005058199A1 (en) * | 2003-12-16 | 2005-06-30 | Avery Dennison Corporation | Electrostatically self-assembled antimicrobial coating for medical applications |
DE10359338B4 (en) * | 2003-12-17 | 2007-07-19 | Heraeus Kulzer Gmbh | Antimicrobial nanosilver additive for polymerizable dental materials |
GB0401821D0 (en) * | 2004-01-28 | 2004-03-03 | Qinetiq Nanomaterials Ltd | Method of manufacture of polymer composites |
US20050256553A1 (en) * | 2004-02-09 | 2005-11-17 | John Strisower | Method and apparatus for the treatment of respiratory and other infections using ultraviolet germicidal irradiation |
US7662176B2 (en) * | 2004-02-19 | 2010-02-16 | Vomaris Innovations, Inc. | Footwear apparatus and methods of manufacture and use |
US7457667B2 (en) * | 2004-02-19 | 2008-11-25 | Silverleaf Medical Products, Inc. | Current producing surface for a wound dressing |
WO2006016263A2 (en) * | 2004-03-03 | 2006-02-16 | Nucryst Pharmaceuticals Corp. | No-containing complexes |
CN1976711A (en) * | 2004-03-18 | 2007-06-06 | 特兰萨维股份有限公司 | Administration of cisplatin by inhalation |
US20070065522A1 (en) * | 2004-03-18 | 2007-03-22 | Transave, Inc. | Administration of high potency platinum compound formulations by inhalation |
US20050271746A1 (en) * | 2004-05-18 | 2005-12-08 | Abbott Chun L | Topical treatments for abnormal biological conditions and method of topically treating such conditions |
US7758892B1 (en) * | 2004-05-20 | 2010-07-20 | Boston Scientific Scimed, Inc. | Medical devices having multiple layers |
CA2566174A1 (en) * | 2004-05-21 | 2005-12-01 | Transave, Inc. | Treatment of lung diseases and pre-lung disease conditions |
DE102004031955A1 (en) * | 2004-06-24 | 2006-01-12 | Paul Hartmann Ag | wound dressing |
US20060002967A1 (en) * | 2004-07-01 | 2006-01-05 | Smestad Thomas L | Resorbable implant with lubricious coating |
US10016583B2 (en) | 2013-03-11 | 2018-07-10 | Thermotek, Inc. | Wound care and infusion method and system utilizing a thermally-treated therapeutic agent |
US10765785B2 (en) | 2004-07-19 | 2020-09-08 | Thermotek, Inc. | Wound care and infusion method and system utilizing a therapeutic agent |
US20060035039A1 (en) * | 2004-08-12 | 2006-02-16 | 3M Innovative Properties Company | Silver-releasing articles and methods of manufacture |
US20060034899A1 (en) * | 2004-08-12 | 2006-02-16 | Ylitalo Caroline M | Biologically-active adhesive articles and methods of manufacture |
CN2734238Y (en) * | 2004-08-25 | 2005-10-19 | 任晓艳 | Nano silver coated suture line |
US20060068024A1 (en) * | 2004-09-27 | 2006-03-30 | Schroeder Kurt M | Antimicrobial silver halide composition |
EP1811963A4 (en) * | 2004-11-08 | 2010-01-06 | Transave Inc | Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally |
WO2006056055A2 (en) * | 2004-11-23 | 2006-06-01 | Inernational Bio-Therapeutic Research Inc. | Method of delivery of therapeutic metal ions, alloys and salts |
JP2008523063A (en) * | 2004-12-06 | 2008-07-03 | ノヴァセントリックス コープ | Antiviral usage of metal nanomaterial composition |
WO2006064788A1 (en) * | 2004-12-13 | 2006-06-22 | Apt Co., Ltd. | Cleaning liquid for oral cavity |
US7749529B2 (en) * | 2005-02-08 | 2010-07-06 | Ash Access Technology, Inc. | Catheter lock solution comprising citrate and a paraben |
WO2006090239A1 (en) * | 2005-02-23 | 2006-08-31 | Kerryne Krause-Neufeldt | Cosmetic product |
DE102005063438A1 (en) * | 2005-02-24 | 2007-12-27 | Lohmann & Rauscher Gmbh & Co. Kg | Process for the preparation of porous sponges from purified marine collagen |
US8864730B2 (en) | 2005-04-12 | 2014-10-21 | Rochester Medical Corporation | Silicone rubber male external catheter with absorbent and adhesive |
US8399027B2 (en) * | 2005-04-14 | 2013-03-19 | 3M Innovative Properties Company | Silver coatings and methods of manufacture |
CN104758961A (en) * | 2005-05-02 | 2015-07-08 | 科洛普拉斯特公司 | A method for sterilising a medical device having a hydrophilic coating |
US20060275223A1 (en) * | 2005-06-02 | 2006-12-07 | Burr James B | Erythritol compositions for teeth and gums |
BRPI0613622A2 (en) * | 2005-07-21 | 2017-05-02 | Fmc Biopolymer As | medical device |
WO2007013100A1 (en) * | 2005-07-26 | 2007-02-01 | Virchow Biotech Private Limited | Gel formulation comprising platelet derived growth factor |
DE102005041005B4 (en) | 2005-08-29 | 2022-10-20 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Biocidal composition containing nanoparticulate silver, the use of this composition and a method for the production of biocidal products using this composition |
US20070185432A1 (en) * | 2005-09-19 | 2007-08-09 | Transport Pharmaceuticals, Inc. | Electrokinetic system and method for delivering methotrexate |
AU2006304908B2 (en) * | 2005-10-18 | 2012-03-22 | Organogenesis, Inc. | Antimicrobial collagenous constructs |
WO2007056236A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with lipid-based platinum compound formulations administered intravenously |
WO2007056263A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously |
US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
US20070190182A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
US20070122350A1 (en) * | 2005-11-30 | 2007-05-31 | Transave, Inc. | Safe and effective methods of administering therapeutic agents |
US20070128247A1 (en) * | 2005-12-01 | 2007-06-07 | Kato Yasushi P | Method for Ionically Cross-Linking Polysaccharide Material for Thin Film Applications and Products Produced Therefrom |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US20070166399A1 (en) * | 2006-01-13 | 2007-07-19 | 3M Innovative Properties Company | Silver-containing antimicrobial articles and methods of manufacture |
US20070166344A1 (en) * | 2006-01-18 | 2007-07-19 | Xin Qu | Non-leaching surface-active film compositions for microbial adhesion prevention |
CA2641021C (en) * | 2006-02-01 | 2015-07-07 | Hollister Incorporated | Methods of applying a hydrophilic coating to a substrate, and substrates having a hydrophilic coating |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
US7687650B2 (en) * | 2006-02-03 | 2010-03-30 | Jr Chem, Llc | Chemical compositions and methods of making them |
US7897800B2 (en) | 2006-02-03 | 2011-03-01 | Jr Chem, Llc | Chemical compositions and methods of making them |
US7927614B2 (en) | 2006-02-03 | 2011-04-19 | Jr Chem, Llc | Anti-aging treatment using copper and zinc compositions |
GB0603487D0 (en) * | 2006-02-22 | 2006-04-05 | Agt Sciences Ltd | Delivery means |
US20070212425A1 (en) * | 2006-03-09 | 2007-09-13 | Barna Ivan J | Cidal formulations and methods of use |
US20070224244A1 (en) * | 2006-03-22 | 2007-09-27 | Jan Weber | Corrosion resistant coatings for biodegradable metallic implants |
US20070224288A1 (en) * | 2006-03-22 | 2007-09-27 | Kiss Nail Products, Inc. | Antibacterial gel coating and pedicure spa with antibacterial function |
EP2001442A4 (en) * | 2006-04-06 | 2013-10-23 | Taro Pharmaceuticals North America Inc | Novel spill-resistant formulations comprising hydrocolloidal polymers |
WO2007116959A1 (en) * | 2006-04-07 | 2007-10-18 | Hisamitsu Pharmaceutical Co., Inc. | Microneedle device and transdermal administration device provided with microneedles |
US8048150B2 (en) * | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
US8273381B1 (en) | 2006-04-14 | 2012-09-25 | Auburn University | Compositions for and methods of controlling olfactory responses to odorants |
US8158137B2 (en) | 2006-04-24 | 2012-04-17 | NM Tech Nanomaterials and Microdevices Technology Limited | Functional nanomaterials with antibacterial and antiviral activity |
ATE473768T1 (en) | 2006-06-14 | 2010-07-15 | Nm Tech Ltd Nanomaterials And | NANOMATERIAL COVERS FOR OSTEOINTEGRATED BIOMEDICAL PROSTHESES |
US20070292397A1 (en) * | 2006-06-19 | 2007-12-20 | Mcnulty Amy K | Method for the detection and neutralization of bacteria |
US20110135742A1 (en) * | 2006-06-20 | 2011-06-09 | The Regents Of The University Of California | Controlled release encapsulated anti-bacterial and anti-inflammatory nanoparticles |
AU2007269440A1 (en) * | 2006-06-30 | 2008-01-10 | Nucryst Pharmaceuticals Corp. | Metal-containing formulations and methods of use |
US8197452B2 (en) * | 2006-07-28 | 2012-06-12 | Becton, Dickinson And Company | Vascular access device non-adhering surfaces |
US8512294B2 (en) * | 2006-07-28 | 2013-08-20 | Becton, Dickinson And Company | Vascular access device antimicrobial materials and solutions |
US20080027410A1 (en) * | 2006-07-28 | 2008-01-31 | Becton, Dickinson And Company | Vascular access device non-adhering membranes |
JP2009545407A (en) | 2006-08-02 | 2009-12-24 | ボストン サイエンティフィック サイムド,インコーポレイテッド | End prosthesis with 3D decomposition control |
WO2008034013A2 (en) * | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Medical devices and methods of making the same |
EP2068782B1 (en) | 2006-09-15 | 2011-07-27 | Boston Scientific Limited | Bioerodible endoprostheses |
US8128689B2 (en) * | 2006-09-15 | 2012-03-06 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis with biostable inorganic layers |
WO2008034047A2 (en) * | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Endoprosthesis with adjustable surface features |
JP2010503481A (en) * | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Medical instruments |
US8808726B2 (en) * | 2006-09-15 | 2014-08-19 | Boston Scientific Scimed. Inc. | Bioerodible endoprostheses and methods of making the same |
EP2066363A2 (en) * | 2006-09-15 | 2009-06-10 | Boston Scientific Limited | Endoprosthesis containing magnetic induction particles |
ATE530210T1 (en) * | 2006-09-18 | 2011-11-15 | Boston Scient Ltd | ENDOPROSTHESES |
JP2010503463A (en) * | 2006-09-18 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Control of biodegradation of medical devices |
JP2010503482A (en) | 2006-09-18 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Endoprosthesis |
US7867522B2 (en) | 2006-09-28 | 2011-01-11 | Jr Chem, Llc | Method of wound/burn healing using copper-zinc compositions |
CN101588715B (en) | 2006-10-12 | 2013-07-10 | Nm技术纳米材料微型装置技术有限公司 | Material, item and products comprising a composition having anti-microbial properties |
US20100098949A1 (en) * | 2006-10-18 | 2010-04-22 | Burton Scott A | Antimicrobial articles and method of manufacture |
US20080097577A1 (en) * | 2006-10-20 | 2008-04-24 | Boston Scientific Scimed, Inc. | Medical device hydrogen surface treatment by electrochemical reduction |
US20080103459A1 (en) * | 2006-10-30 | 2008-05-01 | Anthony Di Salvo | Enzyme inhibition using nanoparticles |
US20080122582A1 (en) * | 2006-11-29 | 2008-05-29 | Texas Instruments Incorporated | Location Based Portable Device Feature Disabler |
US20080132991A1 (en) * | 2006-11-30 | 2008-06-05 | Leonard Pinchuk | Method for Ionically Cross-Linking Gellan Gum for Thin Film Applications and Medical Devices Produced Therefrom |
US20080147734A1 (en) * | 2006-12-18 | 2008-06-19 | Cuticeuticals, Inc | Method of topical steroidal organization |
WO2008083190A2 (en) | 2006-12-28 | 2008-07-10 | Boston Scientific Limited | Bioerodible endoprostheses and methods of making same |
CA2677640A1 (en) * | 2007-02-09 | 2008-08-14 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
WO2008112596A2 (en) * | 2007-03-09 | 2008-09-18 | Anthem Orthopaedics Llc | Implantable device with bioabsorbable layer, kit and method for use therewith, and apparatus for preparing same |
US20080226701A1 (en) * | 2007-03-15 | 2008-09-18 | John Deignan | Medicated patches |
US20080262414A1 (en) * | 2007-04-20 | 2008-10-23 | Transport Pharmaceuticals, Inc. | Single use applicator cartridge for an electrokinetic delivery system and method for self administration of medicaments |
US8309222B2 (en) * | 2007-04-25 | 2012-11-13 | Covidien Lp | Coated filaments |
US20100069957A1 (en) * | 2007-04-25 | 2010-03-18 | Ferass Abuzaina | Coated Filaments |
KR20080070482A (en) * | 2007-05-31 | 2008-07-30 | (주)디딤바이오텍 | A lubricating composition comprising agents which induce the mucosal immunity and a preparation method thereof |
WO2008157485A1 (en) * | 2007-06-15 | 2008-12-24 | Transport Pharmaceuticals, Inc. | Current concentration system and method for electrokinetic delivery of medicaments |
US8133553B2 (en) | 2007-06-18 | 2012-03-13 | Zimmer, Inc. | Process for forming a ceramic layer |
US20080319371A1 (en) * | 2007-06-19 | 2008-12-25 | Transport Pharmaceuticals, Inc. | Method and system for treating of onychomycosis with an applicator having a gel medicament layer |
US8309521B2 (en) | 2007-06-19 | 2012-11-13 | Zimmer, Inc. | Spacer with a coating thereon for use with an implant device |
JP5159183B2 (en) * | 2007-06-22 | 2013-03-06 | アイノベックス株式会社 | Composition for improvement or treatment of infertility |
DE102007031650A1 (en) | 2007-07-06 | 2009-01-08 | Stada Arzneimittel Ag | Dermatology for the treatment and / or care of the skin in atopic dermatitis |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
JP2010540542A (en) * | 2007-09-28 | 2010-12-24 | ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド | Power generation particles and their use |
BRPI0817416A2 (en) * | 2007-10-03 | 2014-10-07 | 3M Innovantive Properties Company | MULTIPLICATION LIMITING PROCESS OF MICROORGANISMS |
ES2319064B1 (en) * | 2007-10-05 | 2010-02-15 | Universidad De Santiago De Compostela | USE OF ATOMIC QUANTIC CLUSTERS (AQCS) AS ANTIMICROBIALS AND BIOCIDES. |
US8608049B2 (en) * | 2007-10-10 | 2013-12-17 | Zimmer, Inc. | Method for bonding a tantalum structure to a cobalt-alloy substrate |
US20110230973A1 (en) * | 2007-10-10 | 2011-09-22 | Zimmer, Inc. | Method for bonding a tantalum structure to a cobalt-alloy substrate |
US20090143855A1 (en) * | 2007-11-29 | 2009-06-04 | Boston Scientific Scimed, Inc. | Medical Device Including Drug-Loaded Fibers |
WO2009079389A2 (en) * | 2007-12-14 | 2009-06-25 | Boston Scientific Limited | Drug-eluting endoprosthesis |
US20090163887A1 (en) * | 2007-12-20 | 2009-06-25 | Arehart Kelly D | Odor control cellulose granules with quinone compounds |
US8273791B2 (en) | 2008-01-04 | 2012-09-25 | Jr Chem, Llc | Compositions, kits and regimens for the treatment of skin, especially décolletage |
US20090187256A1 (en) * | 2008-01-21 | 2009-07-23 | Zimmer, Inc. | Method for forming an integral porous region in a cast implant |
US20090198286A1 (en) * | 2008-02-05 | 2009-08-06 | Zimmer, Inc. | Bone fracture fixation system |
WO2009108147A1 (en) * | 2008-02-27 | 2009-09-03 | Qlt Usa, Inc. | Dapsone to treat rosascea |
US20090255843A1 (en) * | 2008-04-11 | 2009-10-15 | Andrew Charles Krakowski | Systems and kits for treatment methods |
AU2009240513B2 (en) | 2008-04-24 | 2015-03-26 | Medtronic, Inc. | Chitosan-containing protective composition |
JP5738753B2 (en) | 2008-04-24 | 2015-06-24 | メドトロニック,インコーポレイテッド | Rehydratable polysaccharide particles and sponges |
CN102065849B (en) | 2008-04-24 | 2015-04-29 | 麦德托尼克公司 | Protective gel based on chitosan and oxidized polysaccharide |
EP2291524A2 (en) | 2008-04-24 | 2011-03-09 | Medtronic, Inc | Rehydratable thiolated polysaccharide particles and sponge |
US8506944B2 (en) | 2008-05-07 | 2013-08-13 | The Regents Of The University Of California | Replenishment and enrichment of ocular surface lubrication |
DK2915529T3 (en) * | 2008-05-07 | 2017-08-07 | Univ California | Therapeutic regeneration and enrichment of ocular surface lubrication |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8389583B2 (en) | 2008-05-23 | 2013-03-05 | Zurex Pharma, Inc. | Antimicrobial compositions and methods of use |
US8236046B2 (en) * | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US20100004733A1 (en) * | 2008-07-02 | 2010-01-07 | Boston Scientific Scimed, Inc. | Implants Including Fractal Structures |
IT1391669B1 (en) * | 2008-07-23 | 2012-01-17 | Universita' Degli Studi Di Trieste | NANOCOMPOSITE MATERIALS FORMED FROM A POLYSACCHARIDIC MATRIX AND METALLIC NANOPARTICLES, THEIR PREPARATION AND USE |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US20100030170A1 (en) * | 2008-08-01 | 2010-02-04 | Keith Alan Keller | Absorptive Pad |
US20100082088A1 (en) * | 2008-08-27 | 2010-04-01 | Ali Fassih | Treatment of sweating and hyperhydrosis |
US8150525B2 (en) * | 2008-08-27 | 2012-04-03 | Johnson & Johnson Consumer Companies, Inc. | Treatment of hyperhydrosis |
WO2010027189A2 (en) * | 2008-09-02 | 2010-03-11 | 가톨릭대학교 산학협력단 | A new use for homoisoflavanone or a salt thereof |
US8382824B2 (en) * | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
EP2218447B1 (en) * | 2008-11-04 | 2017-04-19 | PharmaSol GmbH | Compositions containing lipid micro- or nanoparticles for the enhancement of the dermal action of solid particles |
US20100124568A1 (en) * | 2008-11-20 | 2010-05-20 | Med-Eez, Inc | Pharmaceutical articles coated with lubricious coatings |
US8551517B2 (en) * | 2008-12-16 | 2013-10-08 | Kimberly-Clark Worldwide, Inc. | Substrates providing multiple releases of active agents |
WO2010085753A1 (en) | 2009-01-23 | 2010-07-29 | Jr Chem, Llc | Rosacea treatments and kits for performing them |
US8267992B2 (en) | 2009-03-02 | 2012-09-18 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
US9149567B2 (en) * | 2009-03-11 | 2015-10-06 | Ansell Limited | Powder-free antimicrobial coated glove |
US20100229282A1 (en) * | 2009-03-11 | 2010-09-16 | Ansell Limited | Powder-Free Anti-Blocking Coated Glove |
EP2229980B1 (en) * | 2009-03-16 | 2015-08-12 | Nuvolase, Inc. | Treatment of microbiological pathogens in a toe nail with antimicrobial light |
US20120089232A1 (en) | 2009-03-27 | 2012-04-12 | Jennifer Hagyoung Kang Choi | Medical devices with galvanic particulates |
CA2974972C (en) * | 2009-05-26 | 2018-12-04 | The General Hospital Corporation | Method and apparatus for dermal delivery of a substance |
US9192626B2 (en) * | 2009-06-10 | 2015-11-24 | American Silver, Llc | Dental uses of silver hydrosol |
JP2012529506A (en) * | 2009-06-10 | 2012-11-22 | エーエクスセラ アクチエボラグ | Use of a composition for treatment of mucositis |
US8821455B2 (en) * | 2009-07-09 | 2014-09-02 | Becton, Dickinson And Company | Antimicrobial coating for dermally invasive devices |
US20110008271A1 (en) * | 2009-07-13 | 2011-01-13 | Jr Chem, Llc | Rosacea treatments using polymetal complexes |
US8814922B2 (en) * | 2009-07-22 | 2014-08-26 | New Star Lasers, Inc. | Method for treatment of fingernail and toenail microbial infections using infrared laser heating and low pressure |
US20110022158A1 (en) * | 2009-07-22 | 2011-01-27 | Boston Scientific Scimed, Inc. | Bioerodible Medical Implants |
US20110065798A1 (en) * | 2009-09-17 | 2011-03-17 | Becton, Dickinson And Company | Anti-infective lubricant for medical devices and methods for preparing the same |
US20110091571A1 (en) * | 2009-10-16 | 2011-04-21 | Moore Michael F | Method of controlling the propagation of mrsa, staph and other infections that colonize in the nose |
AU2010314994B2 (en) | 2009-11-09 | 2016-10-06 | Spotlight Technology Partners Llc | Fragmented hydrogels |
CN102695500A (en) | 2009-11-09 | 2012-09-26 | 聚光灯技术合伙有限责任公司 | Polysaccharide based hydrogels |
ES2617760T3 (en) * | 2009-11-13 | 2017-06-19 | Johnson & Johnson Consumer Inc. | Galvanic device for skin treatment |
US9549842B2 (en) | 2011-02-04 | 2017-01-24 | Joseph E. Kovarik | Buccal bioadhesive strip and method of treating snoring and sleep apnea |
US8701671B2 (en) | 2011-02-04 | 2014-04-22 | Joseph E. Kovarik | Non-surgical method and system for reducing snoring |
JP2011135009A (en) * | 2009-12-25 | 2011-07-07 | Tokyo Electron Ltd | Method and apparatus for drying substrate |
KR20110091461A (en) * | 2010-02-05 | 2011-08-11 | 존슨 앤드 존슨 컨수머 캄파니즈, 인코포레이티드 | Lip compositions comprising galvanic particulates |
CN102781406B (en) * | 2010-03-01 | 2015-07-08 | 强生消费者公司 | Skin care composition having desirable bulk color |
WO2011119573A1 (en) | 2010-03-23 | 2011-09-29 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
US20110236491A1 (en) * | 2010-03-25 | 2011-09-29 | Jeannette Chantalat | Topical anti-inflammatory composition |
US9999702B2 (en) | 2010-04-09 | 2018-06-19 | Kci Licensing Inc. | Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds |
RU2452498C2 (en) * | 2010-07-20 | 2012-06-10 | Общество с ограниченной ответственностью "Научно-производственное объединение "Ликом" | Method for preparing anti-tuberculosis drug |
US9572880B2 (en) | 2010-08-27 | 2017-02-21 | Sienna Biopharmaceuticals, Inc. | Ultrasound delivery of nanoparticles |
DK2608762T4 (en) | 2010-08-27 | 2020-07-20 | Sienna Biopharmaceuticals Inc | COMPOSITIONS AND METHODS FOR TARGETED HEAT MODULATION |
JP5646277B2 (en) * | 2010-10-25 | 2014-12-24 | クラシエホームプロダクツ株式会社 | Disinfectant and acne treatment / prevention agent |
US9572329B2 (en) * | 2010-11-18 | 2017-02-21 | Samuel P Hopkins | Antimicrobial containing fish hook and method of using and manufacturing same |
US8952057B2 (en) | 2011-01-11 | 2015-02-10 | Jr Chem, Llc | Compositions for anorectal use and methods for treating anorectal disorders |
US10086018B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US10245288B2 (en) | 2011-02-04 | 2019-04-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease |
US11523934B2 (en) | 2011-02-04 | 2022-12-13 | Seed Health, Inc. | Method and system to facilitate the growth of desired bacteria in a human's mouth |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11357722B2 (en) | 2011-02-04 | 2022-06-14 | Seed Health, Inc. | Method and system for preventing sore throat in humans |
US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
US9987224B2 (en) | 2011-02-04 | 2018-06-05 | Joseph E. Kovarik | Method and system for preventing migraine headaches, cluster headaches and dizziness |
US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
US10687975B2 (en) | 2011-02-04 | 2020-06-23 | Joseph E. Kovarik | Method and system to facilitate the growth of desired bacteria in a human's mouth |
US10548761B2 (en) | 2011-02-04 | 2020-02-04 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
KR102292017B1 (en) | 2011-02-16 | 2021-08-20 | 더 제너럴 하스피탈 코포레이션 | Optical coupler for an endoscope |
US9707375B2 (en) | 2011-03-14 | 2017-07-18 | Rochester Medical Corporation, a subsidiary of C. R. Bard, Inc. | Catheter grip and method |
US8597264B2 (en) | 2011-03-24 | 2013-12-03 | Kci Licensing, Inc. | Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds |
ES2564672T3 (en) * | 2011-03-30 | 2016-03-28 | Gr Intellectual Reserve, Llc | New suspensions of bimetallic nanocrystals based on gold and platinum, electrochemical preparation processes and uses for them |
GB2497115A (en) * | 2011-12-01 | 2013-06-05 | Lrc Products | Coated condom |
JP6017883B2 (en) * | 2012-08-08 | 2016-11-02 | バイオエポック株式会社 | Manufacturing method of toothpaste |
DK2892524T3 (en) | 2012-09-04 | 2021-01-25 | Eleison Pharmaceuticals LLC | PREVENTION OF PULMONAL CANCER RECYCLING WITH LIPID-COMPLEXED CISPLATIN |
CN102872159A (en) * | 2012-09-29 | 2013-01-16 | 广东同德药业有限公司 | Nano-silver chitosan gel foam preparation for treating vaginal bacterial inflammation, and preparation method thereof |
RU2646809C2 (en) | 2012-10-11 | 2018-03-07 | Нанокомпозикс, Инк. | Silver nanoplates compositions and methods |
CN102872160A (en) * | 2012-10-26 | 2013-01-16 | 广东同德药业有限公司 | Nano-silver foaming agent used for sterilizing wounds of scalds and burns and ulcer wounds |
WO2014066850A2 (en) * | 2012-10-26 | 2014-05-01 | Nanocomposix, Inc. | Metastable silver nanoparticle composites |
US10092728B2 (en) | 2012-11-20 | 2018-10-09 | Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. | Sheath for securing urinary catheter |
US9872969B2 (en) | 2012-11-20 | 2018-01-23 | Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. | Catheter in bag without additional packaging |
US20140377318A1 (en) * | 2012-12-06 | 2014-12-25 | S. Douglas Cornell | Antimicrobial sanitizer systems and methods of killing or inhibiting pathogens |
EP2764876A1 (en) * | 2013-02-11 | 2014-08-13 | Lacerta Technologies Inc. | Bone substitute material with biologically active coating |
US9695323B2 (en) | 2013-02-13 | 2017-07-04 | Becton, Dickinson And Company | UV curable solventless antimicrobial compositions |
US9750928B2 (en) | 2013-02-13 | 2017-09-05 | Becton, Dickinson And Company | Blood control IV catheter with stationary septum activator |
GB2511528A (en) | 2013-03-06 | 2014-09-10 | Speciality Fibres And Materials Ltd | Absorbent materials |
US9750927B2 (en) | 2013-03-11 | 2017-09-05 | Becton, Dickinson And Company | Blood control catheter with antimicrobial needle lube |
US9327095B2 (en) | 2013-03-11 | 2016-05-03 | Becton, Dickinson And Company | Blood control catheter with antimicrobial needle lube |
RU2015143995A (en) | 2013-03-14 | 2017-04-20 | Халлюкс, Инк. | METHOD FOR TREATING INFECTIONS, DISEASES OR DISEASES OF THE NAIL LODGE |
US11000545B2 (en) | 2013-03-15 | 2021-05-11 | Cda Research Group, Inc. | Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza |
US11007143B2 (en) * | 2013-03-15 | 2021-05-18 | Cda Research Group, Inc. | Topical copper ion treatments and methods of treatment using topical copper ion treatments in the oral-respiratory-otic areas of the body |
US11083750B2 (en) * | 2013-03-15 | 2021-08-10 | Cda Research Group, Inc. | Methods of treatment using topical copper ion formulations |
US10398733B2 (en) | 2013-03-15 | 2019-09-03 | Cda Research Group, Inc. | Topical copper ion treatments and methods of treatment using topical copper ion treatments in the dermatological areas of the body |
US20140271919A1 (en) * | 2013-03-15 | 2014-09-18 | Chun Lim Abbott | Topical Copper Ion Treatments and Methods of Treatment Using Topical Copper Ion Treatments in the Genital-Rectal Areas of the Body |
US11318089B2 (en) | 2013-03-15 | 2022-05-03 | Cda Research Group, Inc. | Topical copper ion treatments and methods of making topical copper ion treatments for use in various anatomical areas of the body |
EP2976095B1 (en) * | 2013-03-15 | 2020-12-23 | 3M Innovative Properties Company | Wound healing compositions |
US9095566B1 (en) * | 2013-06-28 | 2015-08-04 | Edward Quicksilver Yavitz | Eyelash and eyelid margin infections |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
CN105979978A (en) | 2013-12-30 | 2016-09-28 | 波士顿科学国际有限公司 | Functionalized Lubricious Medical Device Coatings |
CN104814831A (en) * | 2014-01-30 | 2015-08-05 | 柯惠有限合伙公司 | Preparation of occlusive dressings |
US9789279B2 (en) | 2014-04-23 | 2017-10-17 | Becton, Dickinson And Company | Antimicrobial obturator for use with vascular access devices |
US9675793B2 (en) | 2014-04-23 | 2017-06-13 | Becton, Dickinson And Company | Catheter tubing with extraluminal antimicrobial coating |
US10376686B2 (en) | 2014-04-23 | 2019-08-13 | Becton, Dickinson And Company | Antimicrobial caps for medical connectors |
US10232088B2 (en) | 2014-07-08 | 2019-03-19 | Becton, Dickinson And Company | Antimicrobial coating forming kink resistant feature on a vascular access device |
EP3169378B1 (en) | 2014-08-26 | 2021-09-29 | C.R. Bard Inc. | Urinary catheter |
US9459442B2 (en) | 2014-09-23 | 2016-10-04 | Scott Miller | Optical coupler for optical imaging visualization device |
CN104577135B (en) * | 2015-01-04 | 2017-01-18 | 哈尔滨工业大学 | Preparation method of three-dimensional silver mesh |
US10548467B2 (en) | 2015-06-02 | 2020-02-04 | GI Scientific, LLC | Conductive optical element |
CN113143174A (en) | 2015-07-21 | 2021-07-23 | 图像科学有限责任公司 | Endoscopic accessory with angularly adjustable exit port |
RU2611999C2 (en) * | 2015-08-05 | 2017-03-01 | Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения Российской академии наук | Silver nanocomposite based on arabinogalactan conjugate and flavonoids with antimicrobial and antitumor action and preparation method thereof |
US10040957B2 (en) * | 2015-09-17 | 2018-08-07 | Eastman Kodak Company | Ink jettable, UV-curable compositions |
DE102015115878B4 (en) * | 2015-09-21 | 2018-03-29 | Aap Implantate Ag | A method of treating a metallic surface and bodies having a treated metallic surface |
US10493244B2 (en) | 2015-10-28 | 2019-12-03 | Becton, Dickinson And Company | Extension tubing strain relief |
CN110201242A (en) * | 2016-02-08 | 2019-09-06 | 祥丰医疗私人有限公司 | A kind of medical device |
US10792477B2 (en) | 2016-02-08 | 2020-10-06 | Orbusneich Medical Pte. Ltd. | Drug eluting balloon |
BR102016016340A2 (en) * | 2016-07-14 | 2018-02-06 | Francisco Pianowski Luiz | ANTIMICROBIAN MUCOSAL FORMULATION AND USE OF ANTIMICROBIAN MUCOSAL FORMULATION |
US11330931B2 (en) | 2016-09-29 | 2022-05-17 | Levo Oil Infusion | Apparatus and method for infusing and dispensing oils, and drying and heating infusing materials |
US10537661B2 (en) | 2017-03-28 | 2020-01-21 | DePuy Synthes Products, Inc. | Orthopedic implant having a crystalline calcium phosphate coating and methods for making the same |
US10537658B2 (en) | 2017-03-28 | 2020-01-21 | DePuy Synthes Products, Inc. | Orthopedic implant having a crystalline gallium-containing hydroxyapatite coating and methods for making the same |
EP3675779A1 (en) | 2017-09-19 | 2020-07-08 | C.R. Bard, Inc. | Urinary catheter bridging device, systems and methods thereof |
US10912739B2 (en) | 2017-10-16 | 2021-02-09 | Peace Out Inc. | Hydrocolloid-based skin treatment |
US11648197B2 (en) | 2018-06-28 | 2023-05-16 | Arx, Llc | Dispensing method for producing dissolvable unit dose film constructs |
CN108853557A (en) * | 2018-07-23 | 2018-11-23 | 衢州玛济克医疗科技有限公司 | A kind of wet erythema medical dressing of infant and its production method |
CN109646456A (en) * | 2018-12-31 | 2019-04-19 | 四川金凯医疗器械有限公司 | It is a kind of for treating the new type gel of periodontitis |
CN109731103B (en) * | 2019-01-20 | 2022-03-22 | 桂林理工大学 | Preparation method of P-type molecular sieve-chitosan-sodium alginate-potassium diformate sustained-release antibacterial agent |
US11193184B2 (en) | 2019-02-22 | 2021-12-07 | Cda Research Group, Inc. | System for use in producing a metal ion suspension and process of using same |
RU2730480C1 (en) * | 2019-07-30 | 2020-08-24 | Общество с ограниченной ответственностью "БиоМед" | Method of administering a pharmaceutical substance into a polymer substrate of a dressing |
CN114555072A (en) * | 2020-03-28 | 2022-05-27 | 艾威药业公司 | Aqueous formulation containing povidone-iodine for effective treatment and prevention of viral infections |
DE102021205475A1 (en) | 2021-05-28 | 2022-12-01 | FNT-GmbH | Antimicrobial composition, method of making an antimicrobial composition and use of an antimicrobial composition |
CN113479975A (en) * | 2021-07-01 | 2021-10-08 | 辽宁锦海医药科技有限公司 | Preparation method and application of oxidation potential acidic water |
KR20230081979A (en) * | 2021-11-30 | 2023-06-08 | 경희대학교 산학협력단 | Composition for anti-inflammation comprising gold nanoparticle-peanut sprout extract as an active ingredient |
US11684586B1 (en) | 2022-02-28 | 2023-06-27 | Peace Out, Llc | Anhydrous hydrocolloid matrix comprising homogeneously distributed encapsulated therapeutic agents |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0081599A1 (en) * | 1981-12-10 | 1983-06-22 | Revlon, Inc. | Process for making metallic leafing pigments |
JPS62185807A (en) * | 1986-02-08 | 1987-08-14 | Mitsubishi Shindo Kk | Production of metallic flat powder |
EP0328421A2 (en) * | 1988-02-11 | 1989-08-16 | The Trustees Of Columbia University In The City Of New York | Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same |
WO1993023092A1 (en) * | 1992-05-19 | 1993-11-25 | Westaim Technologies Inc. | Anti-microbial coating for medical devices |
WO1995013704A1 (en) * | 1993-11-18 | 1995-05-26 | Westaim Technologies Inc. | Anti-microbial materials |
WO1998041095A2 (en) * | 1997-03-17 | 1998-09-24 | Westaim Technologies Inc. | Anti-microbial coatings having indicator properties and wound dressings |
US5848995A (en) * | 1993-04-09 | 1998-12-15 | Walder; Anthony J. | Anti-infective medical article and method for its preparation |
WO2000024946A1 (en) * | 1998-10-23 | 2000-05-04 | Avery Dennison Corporation | Process for making metal flakes |
WO2001080920A2 (en) * | 2000-04-17 | 2001-11-01 | Nucryst Pharmaceuticals Corp. | Antimicrobial bioabsorbable materials |
Family Cites Families (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB420052A (en) | 1932-10-17 | 1934-11-23 | Consortium Elektrochem Ind | Manufacture of shaped articles from polyvinyl alcohols |
FR732895A (en) | 1932-10-18 | 1932-09-25 | Consortium Elektrochem Ind | Articles spun in polyvinyl alcohol |
FR882M (en) | 1961-01-18 | 1961-10-06 | ||
GB1270410A (en) | 1969-09-25 | 1972-04-12 | Allor Corp | Colloidal composition and method of preparing the same |
US3757786A (en) | 1970-11-06 | 1973-09-11 | D Smith | Synthetic surgical sutures |
US3800792A (en) | 1972-04-17 | 1974-04-02 | Johnson & Johnson | Laminated collagen film dressing |
US3988434A (en) * | 1972-08-07 | 1976-10-26 | Schole Murray L | Dental preparation |
US3918446A (en) | 1974-05-03 | 1975-11-11 | E Med Corp | Securement device for intravenous catheter and its tubing |
US4059105A (en) | 1976-03-24 | 1977-11-22 | Omnimed, Inc. | Cannula securing device |
DE2748882A1 (en) | 1977-11-02 | 1979-05-03 | Arnis Dr Med Rava | Plaster protecting wound against infection - esp. during application of intravenous catheter, permitting continuous use for ten days |
DE2929706C2 (en) | 1979-07-21 | 1982-09-30 | Drägerwerk AG, 2400 Lübeck | Breathing air humidifiers and warmers for ventilation systems |
US4324237A (en) | 1980-02-26 | 1982-04-13 | E-Med Corporation | Intravenous catheter and tubing securement and dressing device with a window over the puncture or wound site |
GB2073024B (en) | 1980-03-27 | 1984-06-27 | Nat Res Dev | Antimicrobial surgical implants |
WO1981002667A1 (en) * | 1980-03-27 | 1981-10-01 | Nat Res Dev | Antimicrobial surgical implants |
JPS58126910A (en) | 1982-01-21 | 1983-07-28 | Nippon Steel Corp | Dephosphorizing method of molten metal |
GB2140684B (en) | 1983-04-25 | 1986-07-30 | Stavros Christodoulou | Mineral oil composition for use in the treatment of eczema |
JPS6021912A (en) | 1983-07-14 | 1985-02-04 | Mitsubishi Rayon Co Ltd | Manufacture of metallized synthetic fiber staple |
US4828832A (en) | 1983-09-07 | 1989-05-09 | Laboratorios Biochemie De Mexico | Method of manufacturing a composition for treating skin lesions |
EP0136768A3 (en) | 1983-09-07 | 1986-07-30 | Laboratorios Biochemie De Mexico S.A. DE C.V. | Composition and method for treatingskin lesions |
US4581028A (en) | 1984-04-30 | 1986-04-08 | The Trustees Of Columbia University In The City Of New York | Infection-resistant materials and method of making same through use of sulfonamides |
GB8421706D0 (en) | 1984-08-28 | 1984-10-03 | Pharmaceutical Holdings Ltd | Pharmaceutical preparations |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4633863A (en) | 1985-09-27 | 1987-01-06 | Filips Chester P | Arterial anchor bandage |
US4960413A (en) | 1985-11-09 | 1990-10-02 | The Shirley Institute | Wound dressing |
US5122418A (en) | 1985-12-09 | 1992-06-16 | Shiseido Company Ltd. | Composite powder and production process |
US4847049A (en) | 1985-12-18 | 1989-07-11 | Vitaphore Corporation | Method of forming chelated collagen having bactericidal properties |
GB8607159D0 (en) | 1986-03-22 | 1986-04-30 | Smith & Nephew Ass | Pharmaceutical composition |
GB8612598D0 (en) | 1986-05-23 | 1986-07-02 | Tarnpure Ltd | Liquid/gas interface apparatus |
US5236421A (en) * | 1986-05-28 | 1993-08-17 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Fixing system for fastening catheters, cannulas or the like to the skin surface and process for the sterile fastening thereof |
EP0254413A3 (en) | 1986-06-13 | 1989-11-08 | Yoshiaki Matsuo | Silver-ionic water and its uses |
US4952411A (en) * | 1987-02-25 | 1990-08-28 | Trustees Of Columbia University In The City Of New York | Method of inhibiting the transmission of AIDS virus |
US4790824A (en) * | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5143717A (en) | 1987-12-30 | 1992-09-01 | Code Blue Medical Corporation | Burn foam and delivery system |
DE3807944A1 (en) | 1988-03-10 | 1989-09-21 | Braun Melsungen Ag | Device for fastening a catheter or a cannula on the skin surface |
NZ228367A (en) | 1988-03-23 | 1992-02-25 | Smithkline Beecham Corp | Topical composition containing a gold compound for treating inflammatory conditions |
AU4045489A (en) | 1988-08-18 | 1990-03-23 | Konrad Minninger | Silver sulfadiazine containing pharmaceutical product for the local external therapy |
US4956350A (en) | 1988-08-18 | 1990-09-11 | Minnesota Mining And Manufacturing Company | Wound filling compositions |
US4908355A (en) | 1989-01-09 | 1990-03-13 | Dow Corning Corporation | Skin treatment method |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) * | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5270358A (en) | 1989-12-28 | 1993-12-14 | Minnesota Mining And Manufacturing Company | Composite of a disperesed gel in an adhesive matrix |
JP3169621B2 (en) | 1991-01-29 | 2001-05-28 | 株式会社タカミツ | Antimicrobial external preparation |
EP0570452A1 (en) | 1991-02-06 | 1993-11-24 | Minnesota Mining And Manufacturing Company | Improved surgical hardware with bacteriostatic silver coating, and method of using same |
US5484886A (en) * | 1991-04-25 | 1996-01-16 | Merck & Co., Inc. | Human neurokinin-1 receptor |
US5348799A (en) * | 1991-09-03 | 1994-09-20 | Minnesota Mining And Manufacturing Company | Antistatic coatings comprising chitosan acid salt and metal oxide particles |
GEP20002074B (en) | 1992-05-19 | 2000-05-10 | Westaim Tech Inc Ca | Modified Material and Method for its Production |
USD349958S (en) | 1992-07-24 | 1994-08-23 | Bioject Inc. | Needleless injector |
US5383851A (en) * | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
CN1034090C (en) | 1992-08-06 | 1997-02-19 | 蒋建华 | Long-acting broad-spectrum antiseptic fabric and its producing method |
IT1256111B (en) | 1992-11-23 | 1995-11-28 | Lifegroup Spa | SALTS OF TRAUMATIC ACID WITH CICATRIZING AND ANTIBACTERIAL ACTIVITY |
JP2981528B2 (en) * | 1992-12-25 | 1999-11-22 | 三菱電機株式会社 | Cathode ray tube and method of manufacturing the same |
JP3513199B2 (en) * | 1993-01-01 | 2004-03-31 | キヤノン株式会社 | Liquid ejecting head, liquid ejecting head cartridge and recording apparatus using the same, and method of manufacturing liquid ejecting head |
US5631066A (en) | 1993-01-25 | 1997-05-20 | Chronopol, Inc. | Process for making metalized films and films produced therefrom |
US5534288A (en) | 1993-03-23 | 1996-07-09 | United States Surgical Corporation | Infection-resistant surgical devices and methods of making them |
US5454889A (en) * | 1993-08-19 | 1995-10-03 | Ici Canada Inc. | Prill coating |
EP0727427A4 (en) * | 1993-11-05 | 1997-10-15 | Meiji Milk Prod Co Ltd | Antibacterial, antifungal and antiviral agent |
US5454886A (en) | 1993-11-18 | 1995-10-03 | Westaim Technologies Inc. | Process of activating anti-microbial materials |
US5372589A (en) | 1993-11-24 | 1994-12-13 | Davis; W. Gordon | Fenestrated transparent catheter securing device and method |
EP0681841A1 (en) | 1993-11-26 | 1995-11-15 | Kimurakogyo Co., Ltd. | $i(IN VIVO) FREE-RADICAL GENERATOR |
US5817325A (en) | 1996-10-28 | 1998-10-06 | Biopolymerix, Inc. | Contact-killing antimicrobial devices |
JPH07220702A (en) * | 1994-02-02 | 1995-08-18 | Nec Corp | Battery pack |
KR100356882B1 (en) * | 1994-03-28 | 2003-03-10 | 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 | Zinc Gluconate Gel Composition |
US5899880A (en) | 1994-04-08 | 1999-05-04 | Powderject Research Limited | Needleless syringe using supersonic gas flow for particle delivery |
US5563132A (en) | 1994-06-21 | 1996-10-08 | Bodaness; Richard S. | Two-step cancer treatment method |
WO1996004409A1 (en) * | 1994-08-01 | 1996-02-15 | Franz Hehmann | Selected processing for non-equilibrium light alloys and products |
US5578073A (en) * | 1994-09-16 | 1996-11-26 | Ramot Of Tel Aviv University | Thromboresistant surface treatment for biomaterials |
US5569207A (en) | 1994-10-13 | 1996-10-29 | Quinton Instrument Company | Hydrocolloid dressing |
US5589177A (en) | 1994-12-06 | 1996-12-31 | Helene Curtis, Inc. | Rinse-off water-in-oil-in-water compositions |
GB9424562D0 (en) | 1994-12-06 | 1995-01-25 | Giltech Ltd | Product |
GB9502879D0 (en) | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
EP0831858B1 (en) | 1995-06-07 | 2010-04-28 | NEUWIRTH, Robert, S. | Intrauterine chemical necrosing method and composition |
EP0896541A1 (en) | 1995-06-30 | 1999-02-17 | CAPELLI, Christopher C. | Silver-based pharmaceutical compositions |
US6013050A (en) | 1995-10-20 | 2000-01-11 | Powderject Research Limited | Particle delivery |
DE19541735A1 (en) | 1995-11-09 | 1997-05-15 | Iris Roller | Use of hydrothermal rock deposits e.g. calcite precursors |
US5686096A (en) | 1995-12-22 | 1997-11-11 | Becton Dickinson And Company | Medical device for the protection of a catheter penetration site |
US6201164B1 (en) | 1996-07-11 | 2001-03-13 | Coloplast A/S | Hydrocolloid wound gel |
US5895419A (en) * | 1996-09-30 | 1999-04-20 | St. Jude Medical, Inc. | Coated prosthetic cardiac device |
DE19640365A1 (en) | 1996-09-30 | 1998-04-02 | Basf Ag | Polymer-hydrogen peroxide complexes |
EP0834319A1 (en) * | 1996-10-07 | 1998-04-08 | Kartar Dr. Lalvani | Mineral and vitamin combinations in arthritic pain |
GB9623962D0 (en) * | 1996-11-15 | 1997-01-08 | Tillotts Pharma Ag | Pharmaceutical composition |
US6165247A (en) * | 1997-02-24 | 2000-12-26 | Superior Micropowders, Llc | Methods for producing platinum powders |
GB2324732B (en) | 1997-05-02 | 2001-09-26 | Johnson & Johnson Medical | Absorbent wound dressings |
WO1998051273A1 (en) | 1997-05-12 | 1998-11-19 | Sage Pharmaceuticals, Inc. | Topical spray for burn treatment and anti-infection |
US6071543A (en) * | 1997-06-02 | 2000-06-06 | Cellegy Pharmaceuticals, Inc. | Pyridine-thiols reverse mucocutaneous aging |
KR20010013377A (en) | 1997-06-04 | 2001-02-26 | 데이비드 엠 모이어 | Mild, leave-on antimicrobial compositions |
EP0991702B2 (en) | 1997-06-20 | 2017-07-19 | Coloplast A/S | A hydrophilic coating |
DE19728489A1 (en) | 1997-07-03 | 1999-01-07 | Huels Chemische Werke Ag | Medical device for improving the skin fixation of indwelling catheters and other transcutaneous implants with a reduced risk of infection |
US6165440A (en) * | 1997-07-09 | 2000-12-26 | Board Of Regents, The University Of Texas System | Radiation and nanoparticles for enhancement of drug delivery in solid tumors |
US6153210A (en) * | 1997-08-14 | 2000-11-28 | Periodontix, Inc. | Use of locally delivered metal ions for treatment of periodontal disease |
JP3411195B2 (en) | 1997-08-18 | 2003-05-26 | 栄一 築地 | Active oxygen remover |
JPH11116488A (en) | 1997-10-08 | 1999-04-27 | Toagosei Co Ltd | Carcinostatic agent |
JP4039719B2 (en) * | 1997-10-17 | 2008-01-30 | 富士フイルム株式会社 | Antitumor agent |
US6312643B1 (en) * | 1997-10-24 | 2001-11-06 | The United States Of America As Represented By The Secretary Of The Air Force | Synthesis of nanoscale aluminum alloy powders and devices therefrom |
HU221676B1 (en) * | 1998-02-20 | 2002-12-28 | István Budai | Pharmaceutical composition, containing ethanol or water-ethanol solution having iodine and silver nitrate and process for producing it |
FR2775696B1 (en) * | 1998-03-05 | 2000-04-14 | Saint Gobain Vitrage | SUBSTRATE WITH PHOTOCATALYTIC COATING |
US20020014406A1 (en) * | 1998-05-21 | 2002-02-07 | Hiroshi Takashima | Aluminum target material for sputtering and method for producing same |
US6123925A (en) * | 1998-07-27 | 2000-09-26 | Healthshield Technologies L.L.C. | Antibiotic toothpaste |
US6071541A (en) | 1998-07-31 | 2000-06-06 | Murad; Howard | Pharmaceutical compositions and methods for managing skin conditions |
US6238986B1 (en) * | 1998-11-06 | 2001-05-29 | Advanced Micro Devices, Inc. | Formation of junctions by diffusion from a doped film at silicidation |
NZ512267A (en) * | 1998-11-09 | 2003-11-28 | Ira Jay Newman | Ionic silver complex |
US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
US6436422B1 (en) | 1998-11-23 | 2002-08-20 | Agion Technologies L.L.C. | Antibiotic hydrophilic polymer coating |
US6365130B1 (en) * | 1998-11-23 | 2002-04-02 | Agion Technologies L.L.C. | Antimicrobial chewing gum |
US6224579B1 (en) | 1999-03-31 | 2001-05-01 | The Trustees Of Columbia University In The City Of New York | Triclosan and silver compound containing medical devices |
US6258385B1 (en) * | 1999-04-22 | 2001-07-10 | Marantech Holding, Llc | Tetrasilver tetroxide treatment for skin conditions |
JP4454062B2 (en) | 1999-05-17 | 2010-04-21 | 敬 三宅 | Ultrafine particle silver milky body and method for producing the same |
EP1066825A1 (en) * | 1999-06-17 | 2001-01-10 | The Procter & Gamble Company | An anti-microbial body care product |
CN1161511C (en) | 1999-07-27 | 2004-08-11 | 蒋建华 | Long-acting wide-spectrum antiseptic nanometer silver fabric and its making method |
JP2001151681A (en) | 1999-11-24 | 2001-06-05 | Lintec Corp | Prophylactic and/or therapeutic agent for systema digestorium disease |
CN1108786C (en) | 1999-12-28 | 2003-05-21 | 天津市化妆品科学技术研究所 | Silver foil cosmetics |
WO2001049303A1 (en) | 2000-01-06 | 2001-07-12 | Marantech Holding, Llc | Multivalent electron active compositions and methods of making and using same |
US7137968B1 (en) | 2000-03-13 | 2006-11-21 | Nucryst Pharmaceuticals Corp. | Transcutaneous medical device dressings and method of use |
US6224898B1 (en) * | 2000-03-23 | 2001-05-01 | The United States Of America As Represented By The Secretary Of The Army | Antimicrobial dendrimer nanocomposites and a method of treating wounds |
SE516537C2 (en) * | 2000-05-19 | 2002-01-29 | Alfa Laval Ab | Flat pack and plate heat exchanger |
US6592888B1 (en) | 2000-05-31 | 2003-07-15 | Jentec, Inc. | Composition for wound dressings safely using metallic compounds to produce anti-microbial properties |
PT1395289E (en) * | 2000-06-08 | 2011-03-16 | Sang Dr Christine | Treatment of neuropathic pain with a n-methyl-d-aspartate (nmda) receptor antagonists |
US20030170314A1 (en) * | 2000-07-27 | 2003-09-11 | Burrell Robert E. | Compositions of metal-containing compounds |
US7008647B2 (en) * | 2001-04-23 | 2006-03-07 | Nucryst Pharmaceuticals Corp. | Treatment of acne |
ES2231528T3 (en) * | 2000-07-27 | 2005-05-16 | Nucryst Pharmaceuticals Corp. | USE OF NOBLE METALS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS AND DISEASES. |
DE10037353A1 (en) * | 2000-07-29 | 2002-02-07 | Hans E Sachse | Catheter with bioabsorbable coating to prevent rising infections |
CN1279222A (en) | 2000-07-31 | 2001-01-10 | 金华尖峰陶瓷有限责任公司 | Antibacterial inorganic ceramics and its production technology |
CN1291667A (en) | 2000-08-14 | 2001-04-18 | 骏安科技投资有限公司 | Nanometer silver anti-bacteria cloth and its industrial production technology |
CN1147640C (en) | 2000-09-19 | 2004-04-28 | 南京希科集团有限公司 | Antibacterial fabric containing nm-class silver powder and its making method |
CN1159488C (en) | 2001-01-20 | 2004-07-28 | 南京希科集团有限公司 | Antibacterial flexible material containing nm silver and its preparing process and application |
CN1179646C (en) | 2001-04-20 | 2004-12-15 | 朱红军 | Aggregation-preventing nanometer wide-spectrum antibacterial silve powder and its inductrial production process |
JP2004529929A (en) * | 2001-04-23 | 2004-09-30 | ニュクリスト ファーマシューティカルズ コーポレーション | Use of metals for induction of apoptosis and inhibition of matrix metalloproteinases |
CN1183285C (en) | 2001-04-25 | 2005-01-05 | 朱红军 | Aggregation-preventing wide-spectrum nanometer antibiotic silver yarn and its industrial production process |
-
2002
- 2002-04-23 JP JP2002582959A patent/JP2004529929A/en active Pending
- 2002-04-23 DE DE2002610441 patent/DE60210441T2/en not_active Expired - Lifetime
- 2002-04-23 EP EP20020721904 patent/EP1383522B1/en not_active Expired - Lifetime
- 2002-04-23 CA CA 2445729 patent/CA2445729C/en not_active Expired - Fee Related
- 2002-04-23 JP JP2002582960A patent/JP2004529930A/en active Pending
- 2002-04-23 AU AU2002252881A patent/AU2002252881B2/en not_active Ceased
- 2002-04-23 WO PCT/US2002/012690 patent/WO2002085299A2/en active Search and Examination
- 2002-04-23 EP EP02731461A patent/EP1390013A4/en not_active Withdrawn
- 2002-04-23 EP EP20020721903 patent/EP1383521A2/en not_active Withdrawn
- 2002-04-23 EP EP02721902.1A patent/EP1383520B1/en not_active Expired - Lifetime
- 2002-04-23 WO PCT/CA2002/000547 patent/WO2002085385A2/en active IP Right Grant
- 2002-04-23 US US10/131,513 patent/US6723350B2/en not_active Expired - Lifetime
- 2002-04-23 US US10/131,568 patent/US20030021854A1/en not_active Abandoned
- 2002-04-23 WO PCT/CA2002/000548 patent/WO2002085386A2/en not_active Application Discontinuation
- 2002-04-23 CA CA 2445740 patent/CA2445740A1/en not_active Abandoned
- 2002-04-23 CA CA002443587A patent/CA2443587A1/en not_active Abandoned
- 2002-04-23 US US10/128,208 patent/US6989156B2/en not_active Expired - Fee Related
- 2002-04-23 US US10/131,511 patent/US6939568B2/en not_active Expired - Lifetime
- 2002-04-23 CA CA002445734A patent/CA2445734A1/en not_active Abandoned
- 2002-04-23 US US10/131,509 patent/US7087249B2/en not_active Expired - Lifetime
- 2002-04-23 JP JP2002582958A patent/JP2004525980A/en active Pending
- 2002-04-23 AU AU2002303438A patent/AU2002303438B2/en not_active Ceased
- 2002-04-23 AU AU2002252879A patent/AU2002252879B2/en not_active Ceased
- 2002-04-23 WO PCT/CA2002/000549 patent/WO2002085387A2/en active IP Right Grant
- 2002-04-23 ES ES02721904T patent/ES2261659T3/en not_active Expired - Lifetime
- 2002-04-23 AT AT02721904T patent/ATE322274T1/en active
- 2002-04-23 AU AU2002249046A patent/AU2002249046A1/en not_active Abandoned
- 2002-04-23 WO PCT/CA2002/000546 patent/WO2002085384A2/en not_active Application Discontinuation
- 2002-04-23 JP JP2002582875A patent/JP2005507368A/en active Pending
-
2004
- 2004-02-05 US US10/772,672 patent/US20040157073A1/en not_active Abandoned
-
2005
- 2005-07-01 US US11/174,104 patent/US20050271743A1/en not_active Abandoned
- 2005-11-22 US US11/284,507 patent/US20060083792A1/en not_active Abandoned
-
2006
- 2006-05-16 US US11/434,958 patent/US20060204591A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0081599A1 (en) * | 1981-12-10 | 1983-06-22 | Revlon, Inc. | Process for making metallic leafing pigments |
JPS62185807A (en) * | 1986-02-08 | 1987-08-14 | Mitsubishi Shindo Kk | Production of metallic flat powder |
EP0328421A2 (en) * | 1988-02-11 | 1989-08-16 | The Trustees Of Columbia University In The City Of New York | Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same |
WO1993023092A1 (en) * | 1992-05-19 | 1993-11-25 | Westaim Technologies Inc. | Anti-microbial coating for medical devices |
US5848995A (en) * | 1993-04-09 | 1998-12-15 | Walder; Anthony J. | Anti-infective medical article and method for its preparation |
WO1995013704A1 (en) * | 1993-11-18 | 1995-05-26 | Westaim Technologies Inc. | Anti-microbial materials |
WO1998041095A2 (en) * | 1997-03-17 | 1998-09-24 | Westaim Technologies Inc. | Anti-microbial coatings having indicator properties and wound dressings |
WO2000024946A1 (en) * | 1998-10-23 | 2000-05-04 | Avery Dennison Corporation | Process for making metal flakes |
WO2001080920A2 (en) * | 2000-04-17 | 2001-11-01 | Nucryst Pharmaceuticals Corp. | Antimicrobial bioabsorbable materials |
Non-Patent Citations (2)
Title |
---|
PATENT ABSTRACTS OF JAPAN vol. 012, no. 031 (M-663), 29 January 1988 (1988-01-29) -& JP 62 185807 A (MITSUBISHI SHINDO KK), 14 August 1987 (1987-08-14) * |
SANT S B ET AL: "Morphology of novel antimicrobial silver films deposited by magnetron sputtering" SCRIPTA MATERIALIA, ELSEVIER, NEW YORK, NY, US, vol. 41, no. 12, 19 November 1999 (1999-11-19), pages 1333-1339, XP004325908 ISSN: 1359-6462 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
US7763769B2 (en) | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
US8084664B2 (en) | 2001-02-16 | 2011-12-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
US8163974B2 (en) | 2001-02-16 | 2012-04-24 | Kci Licensing, Inc. | Biocompatible wound dressing |
US8735644B2 (en) | 2001-02-16 | 2014-05-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
US8865227B2 (en) | 2007-12-20 | 2014-10-21 | Smith & Nephew (Overseas) Limited | Metal carbonate particles and methods of making thereof |
EP2575915A2 (en) * | 2010-06-04 | 2013-04-10 | Smiths Medical ASD, Inc. | Antimicrobial lubricant |
EP2575915A4 (en) * | 2010-06-04 | 2014-08-06 | Smiths Medical Asd Inc | Antimicrobial lubricant |
CN103501827A (en) * | 2011-03-30 | 2014-01-08 | 大和纺控股株式会社 | Wound-covering material |
RU2659580C1 (en) * | 2017-10-16 | 2018-07-05 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) | Method for obtaining agent for topical treatment of skin lesions based on nanoscale silver particles, ointment base and solid additives |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6723350B2 (en) | Lubricious coatings for substrates | |
US5985308A (en) | Process for producing anti-microbial effect with complex silver ions | |
EP0641224B1 (en) | Anti-microbial coating for medical devices | |
CA2136455C (en) | Process for producing anti-microbial effect with complex silver ions | |
EP1274473B2 (en) | Antimicrobial bioabsorbable materials | |
US7820284B2 (en) | Microbe-resistant medical device, microbe-resistant polymeric coating and methods for producing same | |
AU703141B2 (en) | Anti-microbial materials | |
AU2002303438A1 (en) | Therapeutic treatments using the direct application of antimicrobial metal compositions | |
EP2874671A1 (en) | Anti-microbial gel formulations containing a silver (i) periodate | |
AU2001248193A1 (en) | Antimicrobial bioabsorbable materials | |
CN117414475A (en) | Method for forming antibacterial silica gel catheter by one-step impregnation of aluminum corrosion inhibitor and cuprammonium solution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |